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Type 1 diabetes (T1D) is associated with numerous complications. These include renal and 
cardiovascular disease which are the leading causes of morbidity and mortality in T1D. Renal 
complications also increase the risk for cardiovascular disease. Early detection and treatment 
of their risk factors may help to prevent or at least delay these complications. This dissertation 
examines potential risk factors for altered measures of pulse wave analysis (PWA), which have 
been linked to cardiovascular events and mortality in other populations. It also examines how 
PWA measures relate to prevalent cardiovascular and renal complications in T1D.  
Prospective analyses of potential risk factors for increased arterial stiffness indices, 
augmentation index (AIx) and augmentation pressure (AP), and decreased estimated myocardial 
perfusion, i.e. subendocardial viability ratio (SEVR), showed autonomic neuropathy, smoking 
history, low HDL cholesterol and poorer glycemic control, to be associated with altered PWA 
measures 18 years later.  
Next, cross-sectional analyses between PWA measures and prevalent CVD showed AP 
and SEVR to be significantly related to coronary artery disease and coronary artery calcification, 
respectively, although age was the major predictor of both. AP was also higher, although not 
significantly, and SEVR significantly lower in those with peripheral vascular disease.  
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Finally, SEVR, but not AIx nor AP, was significantly associated with the presence of 
microalbuminuria (MA), and preferentially entered multivariate models over brachial blood 
pressure measures. SEVR was also related to degree of albuminuria in those within the normo- 
and MA range, and was significantly associated, multivariately, with low renal function.  
This dissertation thus yields significant Public Health findings by identifying factors 
(AN, smoking, glycemic control, lipid levels) that may delay increased arterial stiffness (AIx and 
AP) and decreased myocardial perfusion (SEVR). As it additionally shows that these same PWA 
measures are altered in the presence of CVD and renal damage in T1D a potential role for PWA 
measures, especially SEVR, in risk stratification and early intervention for T1D complications is 
apparent.  
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1.0  INTRODUCTION 
Diabetes is the 6th leading cause of death in the United States and the majority of people with 
diabetes die from its complications. Diabetes also contributes to the development of heart disease 
and stroke, the first and third leading causes of death. In fact, heart disease and stroke account for 
about 65% of deaths in people with diabetes [1].  Complications of diabetes can be prevented or 
at the very least delayed; therefore early detection is very important.  
 Increased arterial stiffness (or reduced arterial compliance), is a marker of vascular aging 
and is also associated with cardiovascular risk [2-6]. Arterial stiffness measures increase with 
age [7] as well as in the presence of diabetes [8-10] and end-stage renal failure[11, 12]. 
Microalbuminuria (MA) has been associated with increased arterial stiffness in the general 
population[13] which may be one of the pathways underlying the associations of MA with 
advanced atherosclerosis and cardiovascular mortality. MA is also a marker of early diabetes 
renal disease, itself a risk state for CAD [13, 14]. As changes in arterial stiffness indices can be 
detected prior to the development of clinical disease, markers of arterial stiffness may therefore 
be useful in predicting risk for a number of complications of diabetes. This paper will focus on 
the relatively new technology of radial tonometry to obtain pulse wave analysis (PWA) and 
resulting arterial stiffness indices, augmentation index (AIx) and augmentation pressure (AP) as 
well as subendocardial viability ratio (SEVR), an estimate of myocardial perfusion. In particular 
it will focus on: 
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1. Examining the relationship between risk factors assessed ~18 years prior earlier and PWA 
measures in type 1 diabetes (T1D). 
2.  Determining the relationship between PWA measures and prevalent cardiovascular 
disease (CVD).  Specifically, coronary artery disease (CAD), coronary artery calcification 
(CAC,  a subclinical marker of CAD) and lower extremity arterial disease (LEAD) will be 
assessed. 
3. Examining the relationship PWA measures have with early nephropathy 
(microalbuminuria) and with renal function, both estimated glomerular filtration rate 
(eGFR) utilizing the Modification of Diet in Renal Disease (MDRD) equation and 
Cystatin C measures, in T1D.  
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2.0  BACKGROUND 
2.1 PATHOPHYSIOLOGY OF DIABETES MELLITUS 
Diabetes Mellitus (DM) is a group of metabolic diseases which occurs when the body fails to 
properly metabolize glucose.  In the United States, the National Diabetes Data Group (NDDG) 
criteria for diagnosis and classification of diabetes are used.  Diabetes is diagnosed if an 
individual meets one of three criteria: 1) symptoms of diabetes (polydipsia, polyuria, 
unexplained weight loss) and a casual (without regard to last time of meal) plasma glucose 
concentration of ≥200 mg/dl, 2) a fasting plasma glucose (FPG) (at least 8 hours) ≥126 mg/dl, or 
3) an oral glucose tolerance test (OGTT) 2-hour value ≥200 mg/dl[15]. Individuals with FPG 
levels between 100 and 126 mg/dl are considered to have impaired fasting glucose (IFG).  A 2-
hour post load glucose level between 140 and 199 mg/dl is considered IGT.  Both IFG and IGT 
are referred to as “pre-diabetes”. Individuals with pre-diabetes are at increased risk for 
developing diabetes and cardiovascular disease[16].  
 To maintain glucose homeostasis there must be balance between glucose uptake and 
utilization by the cells and production of glucose by the liver. In a normal fasting state, low 
circulating insulin levels lead to the production of glucose by the liver via gluconeogenesis and 
glycogenolysis, a reduction in synthesis of glycogen as well as a reduction in the uptake of 
glucose by cells requiring insulin for uptake. Postprandially, the increased circulating glucose 
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levels stimulate the secretion of insulin by the beta cells of the islet of Langerhans of the 
pancreas.  The insulin is secreted into the portal venous system, where some is removed by the 
by the liver. The remainder enters the circulatory system, eventually binding to insulin receptors 
of skeletal muscle and fat cells where it aides in the translocation of glucose into cells and thus 
lowers blood glucose levels. The inability to appropriately metabolize glucose in diabetes 
mellitus,  can be due to the failure of the pancreas to produce insulin, as is the case in T1D 
(T1D), or to the inability of the cells to use insulin (insulin resistance) as occurs in Type 2 
diabetes and its early prediabetes state. Failure in either of these areas results in high levels of 
circulating glucose, hyperglycemia.  
 T1D occurs in individuals who are genetically predisposed to the disease. Greater than 
90% of Type 1 cases occur due to autoimmune destruction of beta cells over time. Though 
initiation of this autoimmune response may be triggered by an environmental or infectious 
stimulus, there are many hypotheses as to how and why this occurs, but no solid evidence for 
specific risk factors have been established therefore T1D is currently considered not 
preventable[17]. The autoimmune destruction of the beta cells leads to a reduction and 
eventually, a complete absence of insulin production and secretion. In order for cells to 
metabolize glucose, exogenous insulin must be administered.  
 Type 2 diabetes is thus characterized by peripheral insulin resistance, impaired insulin 
secretion and excessive hepatic glucose production.  The peripheral cells become resistant to 
insulin thereby impairing glucose utilization. The liver also becomes insulin resistant which 
results in decreased uptake of glucose as well as decreased inhibition of hepatic glucose 
production. With reduced insulin sensitivity in peripheral tissues and an increased hepatic 
production of glucose, the result is a state of hyperglycemia. During the initial stage of insulin 
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resistance however, the pancreas will increase its production and secretion of insulin to 
compensate.  Eventually the beta cells become exhausted and production levels of insulin 
decrease[18]. Typical treatment of Type 2 diabetes includes lifestyle/behavioral changes such as 
diet and exercise as well as insulin sensitizing agents.  However, some Type 2 patients will 
eventually need insulin therapy as the beta cells fail to meet the increased demand. It is thought 
that Type 2 diabetes results from a combination of insulin resistance and a beta cell defect, for 
many more subjects have insulin resistance than diabetes. Insulin resistance is often related to 
age and/or obesity. Type 2 diabetes is a very preventable disease. It is usually preceded by 
impaired glucose tolerance (IGT) and approximately 20-50% of people with IGT will progress to 
Type 2 diabetes within 10 years.  Screening of individuals for IGT followed by lifestyle 
interventions could prevent, or at the very least delay the onset of the disease[19-21].  
2.2 DIABETES EPIDEMIOLOGY 
Approximately 20.8 million people in the United States, 7% of the population, have diabetes.  
An estimated 14.6 million are diagnosed; 6.2 million undiagnosed while a further 54 million 
have pre-diabetes (impaired glucose tolerance (IGT) or fasting glucose (IFG))[1].  The World 
Health Organization (WHO) estimated the global prevalence of diabetes to be 171 million (2.8% 
of the population) in the year 2000 and projects that by 2030, 366 million (4.4% of the 
population) people worldwide will have diabetes [22].  The rates of diabetes have increased 
dramatically in the past few decades and will continue to increase due to the aging of the 
population and to the obesity epidemic.  Type 1 accounts for only 5-10% of diabetes cases 
however, the incidence rates of both Type 1 and Type 2 are increasing worldwide[23].  In 1993, 
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T1D affected about 1.4 million people in the U.S. and 10-20 million worldwide[24]. Type 1 
diabetes is the main chronic disease affecting children. The current estimate of Type 1 
worldwide prevalence in children 0-14 years of age is 440,000, or 0.02% of that population with 
an annual increase in incidence of 3%[23]. One in every 400-600 children/adolescents in the 
U.S. has T1D.  Current estimates of U.S. Type 1 annual incidence rates in youth are 14.3, 22.1, 
25.9 and 13.1 per 100,000 for age groups 0-4, 5-9, 10-14 and 15-19, respectively[25]. 
 Development of T1D has both environmental and genetic components. The rates of 
diabetes vary by race and ethnicity as well as by geographical location.  For instance, the highest 
incidence rates of T1D among children ≤14 years, are in Scandinavia with the annual incidence 
in Finland at 41.1 per 100,000. In Sweden, the annual incidence rate among the same age group 
is  range is 31.7 per 100,000, while in Lithuania it is 7.8 per 100,000, one of the lowest rates in 
Europe [23]. The lowest incidence rates known are in China and Japan (1 to 3 per 100,000). 
Accurate estimates of incidence rates of Type 1 in African countries are currently not available. 
Known prevalence rates in African countries are quite low however, this is not necessarily due to 
low incidence, but more likely to high mortality in these areas.  
 The frequency of high-risk HLA alleles (HLA-DR3 and HLA-DR4), which are found in 
about 95% of Type 1 patients, is greater in Caucasians [26-28]. However, studies of 
monozygotic twins show a only a moderate concordance (about 50% or less) and the risk to a 
first degree relative of someone with type 1 is about 5%[29]. In the U.S. the highest incidence 
rates are among Non-Hispanic whites, followed by African Americans, Hispanics, then 
Asian/Pacific Islanders; the lowest incidence rates are in American Indians [25]. The growing 
incidence of T1D is apparent in Non-Hispanic white children as well as in Hispanic and African 
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American children [30, 31]. There is also a seasonality effect in T1D as it is diagnosed more 
frequently in winter and autumn months. This is particularly the case during puberty[32].  
 Both genetic susceptibility and lifestyle factors contribute to the development of Type 2 
diabetes.  There is a strong genetic predisposition to Type 2. The concordance in monozygotic 
twins is approximately 70% [33]. History of Type 2 in a first-degree relative doubles ones risk of 
diabetes and the lifetime risk of Type 2 for a child of two diabetic parents is about 80% [33, 34]. 
However, behavioral and lifestyle factors such as obesity, poor diet and sedentary lifestyle, are 
major contributors to the development of Type 2.  Certain racial/ethnic groups are more 
predisposed to type 2 diabetes than others therefore incidence rates can vary greatly by group 
within one population. Rates of Type 2 diabetes are highest in the Pacific Islands, intermediate in 
the U.S. and India and lowest in China and Russia.  In the U.S., the racial/ethnic group with the 
highest prevalence of Type 2 diabetes is American Indians/Alaska Natives. 15.1% of this group, 
who are 20 years of age or older, has Type 2 and they are 2.2 times more likely than non-
Hispanic whites to have diagnosed -diabetes. 13.3% of non-Hispanic blacks, 9.5% of 
Hispanic/Latino Americans and 8.7% of non-Hispanic whites have Type 2 diabetes[35]. So 
while the rates of T1D are higher in Caucasians, at least within the U.S. rates of Type 2 diabetes 
are much lower in the same population.  
 In the U.S, the total economic cost of diabetes in the year 2002 was estimated to be $132 
billion.  Direct costs were estimated to be $92 billion a drastic increase from the $44 billion spent 
in 1997. Approximately 20% of all health care costs are due to diabetes. A large portion of the 
costs associated with diabetes is due to chronic complications[36].  Beyond the monetary cost 
there is also the personal cost; persons with diabetes have two times the prevalence of physical 
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disability compared to those without diabetes[37].  With the increased incidence of diabetes, 
finding methods to prevent or delay chronic complications is of great importance.    
 
2.3 TYPE 1 DIABETES COMPLICATIONS 
Chronic hyperglycemia leads to chronic complications of diabetes. Many of these complications 
are vascular in nature including microvascular complications such as nephropathy, retinopathy 
and neuropathy as well as macrovascular complications such as peripheral vascular disease, 
coronary artery disease (CAD) and cerebrovascular disease.   
2.3.1 Neuropathy 
Diabetes causes damage to the body’s nerves. Diabetic neuropathies are a family of nerve 
disorders and are classified as 1) peripheral - affecting the limbs, often called Distal Symmetric 
Polyneuropathy (DSP), 2) autonomic – affecting the autonomic nervous system and associated 
organs/functions, 3) proximal - sometimes called lumbosacral plexus neuropathy and affects the 
thighs, buttocks, or hips or 4) focal – muscle pain or weakness caused by sudden weakness of 
one nerve, or a group of nerves. Approximately 50% of people with diabetes will develop some 
form of neuropathy. The most common form is DSP [22] affecting approximately 60% of those 
with T1D over the age of 30 [23]. The risk for diabetic neuropathy increases with increasing 
diabetes duration [24, 25]. 
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2.3.1.1 Peripheral Neuropathy 
 Peripheral neuropathy damages nerves in the arms and legs, typically affecting the feet 
and legs prior to affecting the hands and arms.  Symptoms of peripheral neuropathy include 
numbness/insensitivity, a tingling, burning, or prickling sensation, sharp pains or cramps, 
extreme sensitivity to touch, loss of balance and coordination. Peripheral neuropathy may also 
cause muscle weakness and loss of reflexes.  Due to numbness, sores may occur on the feet and 
go unnoticed. Infection of sores may occur and can spread into the bone resulting in a need for 
amputation. Distal symmetric polyneuropathy (DSP) is the most common form of diabetic 
neuropathy usually developing in the feet. Signs of DSP during clinical examination can include 
signs of sensory loss, initially vibratory and later touch and pain, signs of motor loss such as 
weakness and atrophy, depressed or unelicitable tendon reflexes [26]. 
 In The Pittsburgh Epidemiology of Complications (EDC) Study, by 30 years of diabetes 
duration, over two thirds were affected by DSP [24]. The incidence density of DSP in this study 
was 1.2 per 100 patient years among those with diabetes duration less than 20 years, but 3.83 
among those with duration 20-30 years. The cumulative incidence of DSP in this population at 
20 years ranged from approximately 20-30% while the 25 year cumulative incidence ranged 
from 35-50% (depending on diagnosis cohort: 1965-1969, 1970-1974 and 1975-1980; earlier 
cohort has the highest rate)[27]. Risk factors for DSP in the EDC Study were diabetes duration, 
poor glycemic control (HbA1c level), current smoking, height and hypertension [28].  The 
EURODIAB study, a Type 1 population sampled from 31 populations throughout Europe, found 
an overall prevalence of peripheral neuropathy of 28%. In this study, age (mean = 32.7 ± 10.2 
years), diabetes duration (mean = 14.7 ± 9.3 years) and HbA1c level (mean = 6.7 ± 1.9%), were 
significantly associated with peripheral neuropathy. When adjusting for both age and HbA1c, 
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rates ranged from 11% in those with a diabetes duration of <7 years to 23% in those with 
diabetes duration of 8-14 years, to 38% with a 15 year duration[29]. Diastolic blood pressure and 
total cholesterol were also shown to be independent risk factors for DSP [30].  
2.3.1.2 Autonomic Neuropathy 
 Autonomic neuropathy occurs in diabetes due to damage to the nerve fibers of the 
autonomic nervous system. The autonomic nerve fibers include those that innervate the blood 
vessels and the heart and therefore a common form of autonomic neuropathy is Cardiovascular 
Autonomic Neuropathy (CAN). When damage occurs to these nerve fibers , abnormalities in 
central and peripheral vascular dynamics and heart rate occur[31]. Reduction in heart rate 
variability is the earliest indicator of heart rate. Patients with CAN cannot adequately regulate 
cardiac output or redirect blood flow therefore they tend to have exercise intolerance and 
orthostatic hypotension [32]. Also, since the nerves innervating the heart are affected they can 
also have asymptomatic ischemia and painless myocardial infarction[33]. Relative risk of 
mortality associated with CAN (defined as presence of >2 abnormal quantitative autonomic 
function tests) is was found to be 3.65 (95% C.I.:2.66-4.47) in a pooled estimate of 15 studies 
[34]. 
 In the Pittsburgh EDC Study, incidence density per 100 person-years of symptomatic 
autonomic neuropathy was 0.83 (0.62-1.1) and 0.36 (0.07-1.1) in those with a diabetes duration 
of <20 and 20-30 years, respectively. The overall incidence density was 0.78 (0.59-1.0) per 100 
person-years. Age of onset adjusted cumulative incidence of symptomatic autonomic neuropathy 
ranged from 11-21% in those with diabetes duration of 20 years and from 18-25% in those with 
diabetes duration of 25 years. Incidence of autonomic neuropathy varied by diagnosis cohort, 
which in the EDC study were 1965-1969, 1970-1974, and 1975-1980. Therefore, given the same 
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diabetes duration (20 years), those diagnosed with diabetes later (i.e. between 1975 and 1980) 
were significantly less likely to have incident autonomic neuropathy (cumulative incidence = 
11%) than those diagnosed earlier (i.e. between 1965 and 1969; cumulative incidence = 21%) 
[35].  Autonomic neuropathy is often asymptomatic. However, the presence of asymptomatic 
CAN can be diagnosed by assessing heart rate variability (HRV) using the expiration-to-
inspiration ratio [36]. In the Pittsburgh EDC Study, when CAN was diagnosed by as an abnormal 
(≤1.1) expiration-to-inspiration ratio during deep breathing, the incidence-density over a mean 
follow-up time of 4.7-years was 5.9 /100 person-years. Age (relative risk [RR]=2.15, p=0.0001), 
HbA1 (RR=1.50, p=0.0002) and nephropathy (albumin excretion >200 μg/min) (RR=2.46, 
p=0.0001) were all significant independent predictors of CAN. When nephropathy was not 
available to multivariate models, hypertension was significantly predictive as well[37].  
2.3.2 Eye Complications 
The eye complications associated with diabetes are 1) diabetic retinopathy - damage to the blood 
vessels in the retina, 2) cataract – the clouding of the eye’s lens, cataracts tend to develop at an 
earlier age in people with diabetes; 3) glaucoma – the increase in fluid pressure inside the eye 
which can lead to optic nerve damage and loss of vision. Retinopathy is the  most prominent eye 
associated complication in T1D.  
2.3.2.1 Diabetic Retinopathy 
Retinopathy is the most common eye disease in diabetes and is caused by changes in the 
blood vessels to the retina such as swelling and leakage of fluids or abnormal development of 
blood vessels on the surface of the retina. During the initial, asymptomatic stage, there is 
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decreased retinal blood flow, loss of pericytes and thickening of the retinal basement membrane. 
As the disease progresses, microaneurysms, increased vascular permeability and retinal ischemia 
are present. During advanced stages, fibrovascular proliferation and macular edema occur[38].   
Although improved management of diabetes and glycemic control in recent decades has 
led to a decline in microvascular complications, diabetes is still the leading cause of blindness 
among adults in the U.S. with diabetic retinopathy causing 12,000-24,000 incident cases of 
blindness annually[39]. Diabetic retinopathy is the most common diabetic eye disease and is 
caused by changes in the blood vessels of the retina which usually do not begin to occur until 
after 3-5 years of diabetes duration [40].  
There are various stages of progression of retinopathy. The first stages are the non-
proliferative stages.  In mild non-proliferative diabetic retinopathy (NPDR),  microanerysms are 
present due to weakened capillary walls from pericyte (small cells that can differentiate into 
fibroblasts or smooth muscle cells and are potential blood flow regulators) loss and endothelial 
cell damage.  During this stage, “dot-blot” hemorrhages (ruptures in the capillary walls of the 
deep retinal layers), may also be present. “Hard Exudates” may also form, which are made up of 
lipids leaked from retinal capillaries. In Moderate NPDR, there are microaneurysms as well as 
dilatation of venules (venous beading) and “cotton wool spots” (slowing or halting of movement 
of materials in nerve fibers) due to poor perfusion. Macular edema may also occur at this stage 
due to leaking aneurysms. In severe NPDR, there is noticeable capillary loss, retinal ischemia, 
and greater than 20 intraretinal hemorrhages in each of the four quadrants, venous beading in at 
least two quadrants, or prominent intraretinal microvascular abnormalities in at least one 
quadrant, but no signs of proliferative disease. Finally, in proliferative diabetic retinopathy 
(PDR), there is neovascularization (forming of new but weak blood vessels) and/or 
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vitreous/preretinal hemorrhages[41].  During this stage, severe macular edema can occur, and if 
it is located near the fovea centralis (the center of the macula region of the retina which is 
responsible for sharp central vision), resulting vision loss. The new vessels formed in PDR are 
prone to spontaneous bleeding. They may also undergo fibrosis and contraction resulting in 
detachment of the retina and therefore potential vision loss. Secondary, or Neovascular 
Glaucoma, may also occur due to neovascularization which is accompanied by fibrous tissue that 
blocks drainage of fluid causing its accumulation within the eye and an increase in pressure [38].  
A recent study of a multi-ethnic cohort in the U.S. shows the prevalence rate of 
retinopathy among adults 45-85 with diabetes to be 33.2% and that prevalence is higher among 
blacks (36.7%) and Hispanics (37.4%) than in whites (24.8%) and Chinese (25.7%). Predictors 
of retinopathy were longer diabetes duration, higher fasting glucose level as well as a greater 
waist-hip ratio[42]. In Type 1 diabetes specifically, the crude prevalence of diabetic retinopathy 
was estimated to be between 75-82%. 1 in 300 persons 18 or older have retinopathy due to T1D 
and 1 in 600 has advanced retinopathy that threatens their vision [43]. In the Pittsburgh EDC 
study, prevalence of retinopathy (background or worse) in Type 1 participants age 18-29 years 
ranged from 57% in those with diabetes duration of 5-9 years to 100% in those with duration of 
20-29 years. Prevalence rates of retinopathy increased with increasing duration and with age as 
prevalence rates in those 30 years or older ranged from 93 to 100%[24].  Independent risk factors 
for retinopathy in the EURODIAB study were age, duration of diabetes, HbA1c, as was 
previously stated, as well as weight, current smoking, severe ketoacidosis, macroalbuminuria, 
background and proliferative retinopathy [29]. 
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2.3.3 Nephropathy 
In the United States, diabetic nephropathy is the most common cause of kidney failure, 
accounting for approximately 44% of new cases in 2002 [44, 45]. In the early stages of diabetic 
nephropathy, thickening of the glomerulus (a cluster of blood vessels in the kidney responsible 
for filtering blood and forming urine) occurs. When this occurs, the kidney allows more albumin 
(protein) into the urine resulting in what is called microalbuminuria when the amounts are small 
and later in macroalbuminuria as nephropathy progresses.  Risk factors for nephropathy include 
poor glycemic control, hypertension and lipid levels [27, 46-50].  
 Approximately one third of those with Type 1 develop microalbuminuria and about 15-
25% will develop proteinuria within the first 20 years of diabetes duration[51, 52].  Diabetic 
nephropathy is a major predictor of premature death among Type 1 patients[51, 53] . In The 
Pittsburgh EDC Study, the prevalence rate of microalbuminuria in those ages 18-29 with 
diabetes duration of 5-9 years was 13%. In this same group, prevalence of macroalbuminuria was 
about 2%. By 30 year duration, prevalence of overt nephropathy (AER>200μg/min or renal 
failure) was approximately 40%. Rates of both micro- and macroalbuminuria increased with 
increasing diabetes duration until macroalbuminuria surpassed micro at diabetes duration of 25-
29 years (microalbuminuria ~20%, macroalbuminuria ~18% in females and ~50% in males). In 
the older age group of ≥ 30 years, prevalence rates of macroalbuminuria were significantly 
higher than those of the younger age group with similar diabetes duration [24].  
Microvascular complications are risk factors for cardiovascular disease in T1D, specifically 
microalbuminuria and diabetic retinopathy[54-57].  
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2.3.4 Cardiovascular Complications 
Cardiovascular disease (CVD) occurs with greater frequency in those with diabetes mellitus, a 
finding particularly striking in women [58] whom traditionally are more protected from CVD 
than men.  Atherosclerosis is responsible for the development of many cardiovascular 
complications.  Atherosclerosis is a slow, progressive disease that starts in childhood. It is the 
development of plaques in the walls of arteries which can result in the overall narrowing of the 
arteries or, if the plaque breaks away from the vessel wall, a clot, both of which can restrict 
blood flow to tissues supplied by the specific vessel affected.  Plaque is composed of fat, 
cholesterol, calcium, and other substances found in the blood.  Two major types of plaques exist, 
hard/stable plaques and soft/unstable plaques. Hard plaque causes thickening and hardening of 
vessels while soft plaque is more likely to cause a blood clot.  
 Development of plaques is associated with lipid levels and lipoprotein size. Lipid profiles 
in those with well-controlled T1D without nephropathy or cardiovascular disease, are similar or 
better compared to levels in those without diabetes [59]. However, poor glycemic control[59], 
central obesity, and cigarette smoking[60] are associated with important lipid abnormalities. 
Presence of higher albuminuria levels in T1D have been found significantly associated with 
higher total and LDL cholesterol, triglycerides, and Apo B levels, and lower HDL cholesterol, 
HDL/LDL cholesterol ratio and Apo A/Apo B ratio [46]. Elevated levels of low density 
lipoprotein (LDL) cholesterol, total triglycerides, very low density lipoprotein (VLDL), 
triglycerides and lower level of high density lipoprotein (HDL) cholesterol are associated with 
coronary artery disease in both men and women T1D [61].   The cardiovascular complications of 
T1D include coronary artery disease (CAD), peripheral vascular disease (PVD), cerebrovascular 
disease, all of which are affected by atherosclerosis.  
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2.3.4.1 Coronary Artery Disease 
 Heart disease is the leading cause of diabetes-related deaths [45].   Coronary artery 
disease (CAD) is increased tenfold or greater in those with T1D [62-64]. CAD occurs when 
atherosclerosis results blockages of the coronary arteries . As plaques increase in size, coronary 
arteries narrow and less blood can flow through them. Reduced blood flow means reduced 
perfusion of the heart with oxygen-rich blood. Lack of oxygen to the muscle can result in angina 
(chest pain or discomfort), ischemic ECG changes and/or myocardial infarction (when a blood 
clot forms at the site of plaque in a coronary artery and blood supply is acutely cut off or greatly 
reduced to part of the heart muscle). If the muscle cells of the heart do not receive oxygen, 
permanent damage can occur. Over time, CAD can weaken the heart muscle and contribute to 
heart failure when the heart cannot pump blood effectively to the rest of the body, and 
arrhythmias (changes in the normal beating rhythm of the heart). 
 Incidence density of hard CAD (CAD death, history of MI confirmed by ECG Q-waves 
or hospital records or angiographic stent) in participants of the Pittsburgh EDC study were 0.17 
per 100 patient years for those with diabetes duration less than 20 years and 0.98 per 100 patient 
years with duration 20-30 years. The overall incidence density was 0.36 per 100 patient years 
after 12 years of follow-up.  At 20, 25, 30 years duration cumulative incidence rates were 3.5%, 
8%, 15%, respectively[35].  
 The DCCT found that intensive insulin therapy reduces risk of incident cardiovascular 
disease compared to conventional therapy. Results in epidemiologic studies examining the 
relationship between glycemic control (as determined by glycosylated hemoglobin) and CAD in 
T1D have varied. Lehto et al showed a significant independent association between HbA1 and 
CAD events in men (not women) in their cohort of older-onset T1D participants without renal 
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disease after controlling for traditional risk factors[65]. The Wisconsin Epidemiologic Study of 
Diabetic Retinopathy (WESDR) showed a relationship between HbA1 level and heart disease 
mortality but no significant association with myocardial infarction or angina specifically[66]. In 
the EURODIAB study, HbA1 was not significantly associated with CAD when adjusted for 
traditional CV risk factors beyond age and diabetes duration[67]. Selvin et al reported in their 
meta-analysis that HbA1c was not significantly associated with risk of CAD[68]. However, in 
another meta-analysis improved glycemic control did significantly reduce incident CAD in 
T1D[69]. In the Pittsburgh EDC Study, there was no significant relationship between baseline 
HbA1c and incident CAD at the 10-year [70] or at the 16-year follow-up however, in the 16-year 
follow-up, a positive change in HbA1c from baseline to measurement prior to CAD event was 
significantly associated with CAD risk even after adjustment for traditional risk factors [71].  
 Univariate risk factors for CAD at the most recent (16 year) Pittsburgh EDC follow-up 
were baseline age, diabetes duration, systolic and diastolic blood pressure (and the presence of 
hypertension), serum creatinine, total  and LDL cholesterol levels, triglyceride level, albumin 
excretion rate, presence of nephropathy and smoking status were all positively, significantly 
associated with incident CAD while HDL cholesterol was negatively associated[71]. In 
multivariate analyses, only lower HDL-cholesterol level, higher non-HDL level, longer diabetes 
duration and positive change in HbA1c and AER, and negative change in BMI between baseline 
and follow-up were significantly predictive of CAD. A report of the 10-year follow up from the 
EDC study also showed that insulin resistance (as measured by estimated glucose disposal rate 
(eGDR)) is associated with incident hard CAD (history of MI, fatal CAD, and coronary 
revascularization or coronary artery occlusion ≥50% by angiography) events. There is little sex 
difference in morbidity of CAD in T1D [72], however CAD risk factors do differ by sex[73].  
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For men in EDC, diabetes duration, HDL cholesterol, fibrinogen, hypertension, and smoking 
were significantly associated with incidence of CAD. When nephropathy status was available to 
the model it replaced hypertension, fibrinogen, and smoking. For women, duration, hypertension, 
waist-hip ratio, physical activity, and depressive symptomatology were all significant predictors 
of CAD multivariately[73].   
A major predictor of CAD in T1D is nephropathy[74-78]. The relative mortality from 
CVD is increased 40-fold in T1D patients with nephropathy compared with the general 
population[79].  The association between renal damage and cardiovascular disease may be due to 
its negative effect on prothrombotic factors. The presence of microalbuminuria (small amounts 
of the protein albumin in urine) is associated with increased fibrinogen and coagulation factor 
VIIc in T1D. These factors are more elevated in those with macroalbuminuria compared to those 
micro- and normoalbuminuria [80].  Levels of apo(a) in T1D patients with either 
microalbuminuria or macroalbuminuria but no CAD are comparable to CAD patients without 
diabetes. But in T1D patients without microalbuminuria apo(a) levels are normal[81]. Potentially 
atherogenic lipoprotein profiles are also associated with the presence of albuminuria in T1D. 
Jensen et al found that plasma total cholesterol, very low density lipoprotein (VLDL) cholesterol, 
low density lipoprotein (LDL) cholesterol, triglyceride and fibrinogen levels increase with 
increasing urinary albumin excretion but that HDL cholesterol levels were unaffected by 
albuminuria [82]. In the DCCT/EDIC study, medium, and small VLDL were associated with 
albumin excretion rate (AER) in both men and women. Large VLDL and intermediate density 
lipoprotein (IDL) was associated with AER in men only. This study also found that LDL particle 
concentration and ApoB were positively associated with AER, that there was a borderline 
inverse association between LDL diameter and AER in men and that small HDL was positively 
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associated with AER[83]. In the Pittsburgh EDC cohort, lipid mass and particle concentrations 
VLDL subclasses, small LDL, medium LDL, and medium HDL were significantly higher in 
CAD cases compared to non-cases, and large HDL was decreased[78]. Another factor that may 
link albuminuria and CAD is its association with left ventricular (LV) dysfunction. Guglielmi et 
al found that increased LV mass, higher wall thickness to radius ratio and impaired LV 
relaxation are significantly higher in microalbuminuric T1D patients compared to those with 
normoalbuminuria and to controls [84].   
2.3.4.2 Peripheral Vascular Disease 
 Peripheral Vascular Disease (PVD) is a disease of blood vessels, often leading to 
narrowing of blood vessels that are outside the heart and brain. Lower-Extremity Arterial 
Disease (LEAD) is a specific type of PVD in which the lining of blood vessels in the legs and 
feet become damaged, leading to buildup of cholesterol and other lipids, causing the arterial wall 
inner lining to thicken. As the atherosclerosis worsens, the arteries become narrowed or blocked, 
causing blood flow to decrease. Reduce blood flow to tissues causes can lead to foot ulcers 
(possibly resulting in amputation) as well as specific symptoms of claudication: discomfort, 
cramps, or pain in the hips, thighs or calves with walking. The ankle-brachial index (ABI) is 
used to measure to determine if PAD/LEAD is present.  ABI is measured by taking the brachial 
and ankle systolic pressures. The higher systolic pressure of the anterior tibial or posterior tibial 
measurement for each foot is then divided by the highest brachial systolic pressure to obtain an 
ankle brachial pressure ratio. An ABI less than 1.0 is considered abnormal and symptoms of 
claudication typically occur when ABI is less than 0.9.  In persons with diabetes, calcification of 
the arteries can occur which hardens the arteries and in turn elevate ABI[85]. Determining the 
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presence of LEAD in T1D often takes into account ABI, history of claudication and lower 
extremity amputation.  
 In The Pittsburgh EDC study population traditional cardiovascular risk factors that 
multivariately predicted incident LEAD were diabetes duration, HbA1, LDL cholesterol and 
smoking status[86]. Further evaluation showed that increased albumin excretion rate (AER), the 
presence of hypertension, and increased heart rate were significantly associated with 10-year 
incidence of LEAD in both males and females. Diabetes duration, HbA1 and AER were 
predictors in males only, while estimated glucose disposal rate (eGDR) and diabetes duration 
were predictive in females[87].  PVD is a strong predictor of  cardiovascular events [88, 89] and 
is twice as common among those with diabetes[90, 91]. 
2.3.4.3 Cerebrovascular Disease 
 Cerebrovascular disease is a disease of the blood vessels, especially the arteries that 
supply the brain. It is usually caused by atherosclerosis and can lead to a stroke. Stroke is an 
interruption of blood supply to part of the brain. This interruption is usually caused by blockage 
of the arteries or blood vessels that lead to the brain, termed Ischemic Stroke. Ischemic stroke is 
the most common type of stroke and is a result of atherosclerosis.  The build-up of plaque over 
time causes abnormal blood flow and possibly clots. Clots are referred to as cerebral thrombus if 
they are stationary in the brain or cerebral embolism if they break loose from elsewhere and 
move through the circulatory system to the brain. Hemorrhagic stroke is a second type of stroke 
which is caused by the bursting of weak blood vessels in the brain[92].  The risk of stroke in 
patients with T1D has been assessed in epidemiological studies. In a multinational study, 
increased risk of stroke mortality was observed among individuals with type 1 and type 2 
diabetes, but there was considerable variation among countries[93, 94]. Risk of total stroke, but 
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not hemorrhagic stroke mortality, in a U.K. T1D cohort was increased compared to those among 
the general population [95]. Total stroke mortality was also found to be 4.8-fold higher in women 
with T1D than in nondiabetic women [96]. In the Nurses’ Health Study, T1D was associated with 
a 6.3-fold higher risk of ischemic stroke and a nearly 4-fold higher risk of hemorrhagic stroke 
than women without diabetes, even after controlling for age, BMI, and other cardiovascular risk 
factors[97].  
 The WHO multinational study of vascular disease in diabetes showed that independent 
risk factors for stroke in T1D are systolic blood pressure and proteinuria in both men and 
women. Additionally, probable ECG changes significantly increased risk in T1D men [93].  
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2.4 VASCULAR AGING AND ARTERIAL STIFFNESS 
2.4.1 The Vasculature 
The arterial tree of the vascular system functions to deliver oxygenated blood from the left 
ventricle of the heart through the aorta to large arteries, then to the arterioles and finally the 
capillaries of tissues and organs. In doing so, it also regulates the flow of blood so that there is 
continuous flow during systole (the contraction of the heart’s ventricles) and diastole (the 
relaxation period) as well as the reflection of blood back towards the heart for reoxygenation and 
coronary perfusion.  The aorta, large arteries, and the arterioles are made up three layers; 1) a 
connective tissue outer layer (adventitia); 2) a middle layer of smooth muscle (media); and 3) an 
inner layer of endothelial cells and some subendothelial connective tissue (intima).  The aorta 
and the large arteries contain a large amount of elastic tissue, so after stretched during systole by 
the ejection of blood from the left ventricle, the vessels are able to recoil during diastole.  This 
arterial recoiling is important as it helps to propagate the blood forward throughout the arterial 
tree and also allows for coronary perfusion during diastole.  Arterioles are different from the 
aorta and large arteries because they contain less elastic tissue but more smooth muscle thereby 
creating resistance and slowing down blood flow[98]. The peripheral resistance created by the 
arteries and arterioles cause a reflected wave back to the heart. The pulse-wave velocity, the 
speed at which the forward pressure wave created by the contraction of the left ventricle is 
transmitted from the aorta to the vascular tree, as well as the distance to peripheral reflecting 
sites, determine the timing of the wave reflection. In healthy, young individuals the reflection 
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wave typically reaches the heart during diastole which aides in coronary perfusion.  Also, this 
wave reflection limits the pressure to the periphery where damage to the microcirculatory beds 
might occur [99]. Increases in arterial stiffness, i.e. increases in the rigidity of arterial walls 
[100], increases the speed at which forward and reflected waves travel [101]. Therefore, reflected 
waves occur earlier, eventually occurring during systole rather than diastole, augmenting systolic 
blood pressure while lowering diastolic blood pressure creating a state of isolated systolic 
hypertension (ISH), thereby increasing cardiac afterload and decreasing coronary perfusion. 
Meanwhile, forward waves have increased pulsatile velocity flowing into microcirculation 
potentially causing damage. 
2.4.2 Arterial Stiffness Measures and Indices 
Many indices can be used to quantify arterial stiffness; terms and definitions of which are 
provided in Table 1 (adapted from O’Rourke, et al. [102] and Mackenzie et al. [100]).  Multiple 
factors can influence these indices, such as assumed values of cardiac output that are poorly 
validated; they may relate proximal diameter change to pressure change at distant sites; or they 
may be influenced by heart rate or cardiac contractility [100].  
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Table 1.  Definitions, formulae, units for measures of arterial stiffness, compliance or distensibility 
TERM DEFINITION FORMUAE UNITS 
Arterial Distensibility Relative diameter 
change for a pressure 
increment 
ΔD/ΔPxD mmHg-1 
Arterial Compliance Absolute diameter 
change for a given 
pressure increase at 
fixed vessel length 
ΔD/ΔP cm/mmHg 
Elastic Modulus Pressure change 
required for 100% 
stretch from resting 
diameter (fixed vessel 
length) 
ΔP*D/ΔD mmHg 
Young’s Modulus Elastic Modulus per 
unit area 
ΔP*D/ΔDxh mmHg/cm 
Stiffness Index Ratio of Ln(Systolic 
pressure / diastolic 
pressure) : relative 
change in diameter 
Β=Ln(Ps/Pd)/[Ds-Dd/Dd) No Units 
Augmentation Index Difference between the 
2nd and 1st systolic 
peaks as a percentage of 
pulse pressure 
[(P2-P1)/(PP)] x 100 % 
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Pulse pressure, the difference between systolic blood pressure (SBP) and diastolic blood 
pressure (DBP), is a well known surrogate marker for systemic arterial stiffness[103]. Although 
SBP and DBP tend to increase with age[104], after approximately the 5th decade of life ISH 
tends to occurs as does a decline in diastolic blood pressure resulting in greater pulse pressure 
(PP). PP is a simple measure of arterial stiffness as it can be measured by the use of a standard 
sphygmomanometer. However, PP is not the most accurate marker of arterial stiffness as it does 
not necessarily accurately reflect central pulse pressure[105]. Pulse pressure is a better predictor 
of coronary heart disease than SBP or DBP alone in hypertensive patients over 50 [106, 107].  
Central pulse pressure has been shown to be an independent predictor of all cause mortality in 
ESRD [108], and of cardiovascular events in those with hypertension[2].  
 The speed at which the forward pressure wave is transmitted from the aorta to the 
remainder of the arteries and arterioles is known as pulse-wave velocity. The measurement of 
PWV is determined by measuring the time it takes for the arterial waveform to pass two reading 
sites (typically carotid and the femoral arteries) a measured distance apart. This measurement 
gives information about the distensibility of the vessel being studied rather than information 
about systemic arterial stiffness [100]. There are invasive and non-invasive techniques for 
measuring PWV. Non-invasive carotid-femoral PWV is considered the “gold-standard” 
measurement of arterial stiffness [101].  PWV is considered the gold-standard because it is based 
on direct measurements of parameters linked to regional arterial stiffness and carotid-femoral 
PWV specifically, is considered clinically relevant as this measures pressure and stiffness within 
the aorta and large arteries which are closest to and most influential on the heart[101]. Also, 
many of the studies that have examined arterial stiffness measures in relation with adverse 
outcomes have utilized PWV, therefore the risk associated with higher PWV is more understood  
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than for other measures of arterial stiffness [109]. However, problems that arise with this PWV 
measurement include use of superficial arteries as central arteries are inaccessible, estimating 
actual distance between recording sites, reduced accuracy if sites are close in proximity [100]. 
Also, in the presence of metabolic syndrome, diabetes, peripheral artery disease and obesity, the 
femoral pressure waveform can be difficult to record accurately[110]. 
 As previously mentioned, numerous longitudinal studies have reported the independent 
predictive value of arterial stiffness for mortality and CVD. For example, aortic Pulse Wave 
Velocity (aPWV) has been show to predict all cause mortality in the elderly[111, 112], and in 
those with impaired glucose tolerance (IGT)[113], or cardiovascular mortality in those with end-
stage renal disease (ESRD)[3], hypertension[4], and in the general population[5, 6]. 
 Ultrasound technology is also used to measure arterial stiffness by measuring 
distensibility and compliance (the inverse of stiffness). This technique is limited to larger and 
accessible arteries such as the brachial, femoral, carotid arteries and the abdominal aorta and can 
be operator-dependent[100]. Simultaneous measurement of blood pressure during ultrasound of 
arteries is necessary. The use of ultrasound to measure arterial stiffness can be expensive and 
inconvenient due to the size and cost of equipment.  Studies that have utilized B-Mode 
Ultrasonography to measure distensibility (the inverse of stiffness), have shown that reduced 
distensibility (i.e. increased stiffness) is an independent predictor of cardiovascular outcomes. 
For instance, Tsivgoulis et al. showed in a case-control study, that reduced common carotid 
artery (CCA) distensibility was independently associated with ischemic stroke even after 
adjusting for blood pressure values, diastolic common carotid arterial diameter and height [114]. 
Stork et al. showed that the calculated Young’s Elastic Modulus from B-Mode measures of 
distensibility are predictive of cardiovascular mortality in elderly men[115].  Liao et al. also used 
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B-mode ultrasonography using its measurements to calculated Peterson’s Elastic Modulus, 
Young’s Elastic Modulus, and the beta stiffness index finding that after adjustment for age, 
gender, ethnicity, smoking status, HR, obesity and education, a lower modulus or higher beta 
stiffness index was significantly associated with risk for incident hypertension over a 6-year 
follow-up. These findings were independent of risk factors for hypertension and baseline blood 
pressure[116]. 
 There are multiple non-invasive devices available to measure and analyzed the arterial 
waveform.  Applanation tonometry is used to record pressure at either the radial or carotid artery.  
A transfer function is then used to derive central aortic waveforms which can be used to calculate 
central blood pressure, the amount of central systolic pressure due to pulse wave reflection 
(augmentation pressure (AP)) and augmentation index (AIx), the AP as a percentage of the pulse 
pressure (AIx=(AP/PP) X100) . Carotid AIx has been shown to independently predict all cause 
cardiovascular mortality in ESRD [117]. Pulse wave analysis is influenced by vasoactive 
drugs[118], AIx and AP increase with mean arterial pressure (MAP)[119], and are inversely 
related to body height[120] and heart rate[121]. Arterial stiffness increases with increasing age.  
A significant relationship between aging and arterial stiffness as measured by a variety of 
techniques, has been found in numerous cross-sectional studies and a recent study showed that 
the relationship to be curvilinear in nature[7].  Physiological factors attributed to the aging of the 
vasculature include progressive thickening of the intima-media[122]. Between 20 and 90 years 
of age, carotid intima medial thickness (CIMT) increases threefold[123]. This thickening is 
largely due to intimal hyperplasia[124]. However, the elasticity of the media is also reduced as 
elastin lamellae thin and become separated[125].  In the larger elastic arteries there is increase in 
both collagen content and covalent cross-linking of collagen reducing compliance.  Arterial 
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stiffness is also shown to increase due to atherosclerosis development, the slow buildup of 
plaques composed of fat, cholesterol, and especially calcium, on the inside of walls of the 
arteries[126].  Lack of physical activity[127], obesity[128], smoking[129], hypertension[130], 
hypercholesterolemia[131], impaired glucose tolerance[132], Type 2 diabetes[133], and T1D[10, 
134, 135] are associated with increased arterial stiffness as well. 
 Alterations in the function of endothelial cells lining the vasculature, termed “endothelial 
dysfunction”, also occur with increasing age. There is an increase in endothelin, a potent vaso-
constrictor and procoagulant[136]. Most important however, is the loss of active/bio-available 
nitric oxide (NO), which is essential in maintaining vascular tone and reactivity[137] as well as 
vasodilatation.  Oxidative stress, the build-up of oxygen free radicals, occurs with age and in the 
presence of cardiovascular risk factors such as hyperlipidemia, high blood pressure, smoking and 
diabetes. These oxygen free radicals directly inactivate NO [138] thereby reducing NO 
bioavailability causing endothelial dysfunction[139, 140].  
 Hyperglycemia induces endothelial dysfunction and reduces endothelium-dependent 
relaxation[141, 142] due to increased production of reactive oxygen species[143-145]. 
Mechanisms potentially involved in development of endothelial dysfunction due to 
hyperglycemia include increased formation of glucose-derived advanced glycation end-
products[146]; glucose-induced activation of protein kinase C isoforms[147]; and increased 
glucose into the aldose reductase pathway increasing production of sorbitol[148].  Endothelial 
dysfunction and arterial stiffness are both associated with diabetes however, studies examining 
the association between measures of endothelial dysfunction and measures of arterial stiffness 
show conflicting results [8, 149-152].  Berry et al. measured systemic arterial compliance and 
endothelium-dependent flow-mediated dilation (FMD) of the right brachial artery in a group of 
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T1D free of overt micro- and macrovascular complications and a group of control subjects.  
Although arterial compliance was 29% lower in the T1D group compared to controls, 
compliance was not significantly related to FMD in the T1D group[8]. In a group of participants, 
the majority with hypertension, arterial stiffness as measured by pulse wave analysis and FMD 
were not significantly correlated[152]. Nigam et al. did find a significant association between 
arterial stiffness and percent flow-mediated dilation in patients with risk factors for CAD and 
those with established CAD [149]. Nakamura et al. also found a significant association between 
FMD and both arterial compliance and distensibility in CHF patients[150]. Jadhay et al. showed 
that PWV was significantly associated with FMD of the brachial artery in a mixed group of 
participants with hypertension and/or type 2 diabetes.  
2.4.3 Arterial Stiffness and Type 1 Diabetes 
Isolated increased systolic blood pressure and decreased diastolic blood pressure with the 
resulting increase in pulse pressure appear to occur earlier in Type 1 diabetes indicating possible 
accelerated arterial aging [153]. Through measurement of pulse wave velocity, Berry et al 
showed that arterial compliance is reduced by approximately 29% in those with T1D compared 
to controls. The Type 1 participants of the study had no evidence of overt micro- or 
macrovascular disease. This study also measured flow mediated dilation (FMD), a measure of 
endothelial dysfunction, and examined whether there was a significant relationship between 
PWV and FMD; there was not[8].  Brooks et al utilized pulse wave analysis via radial 
applanation tonometry to measure arterial stiffness  indices in type 1 diabetes study participants 
and controls finding that T1D increased aortic AIx as well as reduced estimated myocardial  
perfusion (as determined using the subendocardial viability ratio (SEVR))[9].  Haller et al used 
30 
the same technique demonstrating that arterial stiffness indices were significantly higher in 
children with T1D compared to controls[10]. However, Ryden et al found arterial stiffness 
measured non-invasively by sonography of the abdominal aorta and common carotid arteries  to 
be significantly higher in women, but not in men, with T1D compared to controls[154]. These 
findings held true at a 7-year follow-up[155].  Age is significantly associated with pulse pressure 
in T1D as it is in the general population; however this association is stronger in the presence of 
micro- or macroalbuminuria and/or retinopathy[156]. Acute hyperglycemia is also associated 
with increased arterial stiffness in T1D[157] and insulin resistance in T1D seems to affect typical 
decreases in large artery stiffness associated with normal insulin action [158]. 
 Some studies have examined the potential link between endothelial dysfunction and 
arterial stiffness in T1D.  A cross-sectional examination within The EURODIAB study found 
that advanced glycation end products (AGE’s) were significantly associated with pulse pressure 
in T1D [135] suggesting a potential link between oxidative stress and endothelial dysfunction 
with arterial stiffness. However, Haller et al showed that superoxide dismutase activity and NO 
are not correlated with arterial stiffness 
2.4.4 Pulse Wave Analysis via Applanation Tonometry 
The SphymoCor Pulse Wave Analysis device (Atcor, Sydney, Australia) uses applanation 
tonometry to record peripheral arterial waveforms. These waveforms are used to derive central 
aortic waveforms by applying a generalized transfer function. Studies have shown that there 
exists good consistency between measured and derived waveforms as well as the values 
calculated from these waveforms[159, 160].   Pauca et al. compared SphygmoCor derived 
waveforms to directly measured aortic waveforms, finding a high correlation between the two 
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[161]. In the study, ascending aortic and radial artery pressure waves were recorded 
simultaneously in 62 anesthetized patients prior to the initiation of cardiopulmonary bypass. A 
generalized transfer function was used to generate ascending aortic pressure waveforms from the 
radial pulse. Estimated aortic pulse waveforms were compared with simultaneously recorded 
aortic waves. The two different waveforms were then compared for systolic, diastolic, mean, and 
pulse pressures. When radial estimated and directly measured aortic pressure waveforms were 
compared, there was good correspondence for systolic (mean 0.0±4.4 mm Hg), pulse (0.7±4.2 
mm Hg), mean (0.5±2.0 mm Hg) and diastolic (0.6±1.7 mm Hg) pressures.  
 Numerous variables associated with vascular stiffness can be obtained using the 
SphgymoCor device, which are detailed in Table 2. Studies show a high level of repeatability 
and reproducibility of SphygmoCor pulse wave analysis measurements.  Savage et al. examined 
intra-observer, inter-observer and long-term reproducibility of pulse-wave analysis utilizing the 
SphygmoCor device in patients with chronic renal failure and in health controls. This study 
found that measurements of central aortic mean blood pressure (MBP), indices of arterial 
stiffness and the subendocardial viability ratio (SEVR) showed excellent reproducibility in all 
the studies[162]. Wilkinson et al also found good inter-observer reproducibility of AIx measures 
using the SphygmoCor device in a mixed group of subjects with and without a wide range of 
cardiovascular risk factors [163].  Papaioannou et al. demonstrated good intra- and inter-observer 
reproducibility of pulse-wave analysis measures of AIx and reflection time intervals in those 
with low blood pressures [164]. Crilly et al. completed at repeatability study using inexperienced 
operators also finding excellent inter- and intra-observer reproducibility over time and across a 
range of AIx measures[126]. 
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Table 2. Measures obtained by the SphygmoCor Vx Pulse Wave Analysis Device 
PARAMETER DESCRIPTION FORMULAE UNITS 
Augmentation 
Pressure (AP) 
A measure of contribution the 
reflected wave makes to the 
systolic aortic pressure; 
Pressure difference between the 
1st peak  and the 2nd Peak AP = P2-P1 mmHg 
Augmentation Index 
(AIx) 
AP as a proportion of central 
pulse pressure (PP). AIx = (AP/PP)x100 % 
Subendocardial 
Viability Ratio 
(SEVR) 
Ratio of diastolic area/min 
(Tension Time Index (TTI)) 
and Systolic area/min (Diastolic 
Time Index (DTI)) SEVR = (DTI/TTI)x 100 % 
Ejection Duration 
(ED) 
The period of time from the 
start of the cardiac cycle (T0, 
aortic valve open) to the end of 
systole (incisura). ED =T(incisura)-T0 msec 
Aortic Systolic Blood 
Pressure (aSBP) 
Maximum pressure of the 
central waveform  mmHg 
Aortic Diastolic 
Blood Pressure 
(aDBP) 
Minimum pressure of the 
central waveform  mmHg 
Aortic Pulse Pressure 
(aPP) 
Difference between aortic 
systolic and diastolic pressures aPP = aSBP-aDBP mmHg 
HR 
The average heart rate over the 
captured 10-second data capture 
period  bpm 
End Systolic Pressure 
(ESP) Pressure at end of systole  mmHg 
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3.1 ABSTRACT 
BACKGROUND:  Cardiovascular disease occurs earlier age and with greater frequency in Type 
1 diabetes (T1D).  Arterial stiffness indices (augmentation index (AIx) and augmentation 
pressure (AP)), are increased in T1D and are associated with CAD risk.  Subendocardial viability 
ratio (SEVR), an estimate of myocardial perfusion and an indicator of potential for myocardial 
ischemia, is significantly reduced in T1D. Autonomic neuropathy (AN), a known T1D 
complication, affects blood pressure and heart rate regulation and is an independent risk factor 
for cardiovascular morbidity and mortality. We therefore evaluated the predictive value of AN 
for AIx, AP and SEVR in T1D. 
METHODS:  Baseline autonomic nerve function was measured in participants in The Pittsburgh 
EDC Study of childhood onset T1D by heart rate variability during deep breathing. The ratio of 
R-R interval length during expiration to inspiration (E/I ratio) was calculated. Other 
cardiovascular and diabetes factors were also assessed. Pulse wave analysis (PWA) was 
performed using SphgymoCor Px on 144 participants at 18 year examination.  Multivariate 
regression was performed for each PWA measure with baseline factors and adjustment for 
concurrent potential confounders.  
 RESULTS: Lower baseline E/I ratio and HDL-cholesterol, and smoking history were associated 
with higher AIx and AP, and lower SEVR at follow-up (18 years later).  Higher baseline HbA1 
was also associated with higher AP and lower SEVR.  
CONCLUSIONS: AN is associated with increased arterial stiffness indices and decreased 
estimated myocardial perfusion in T1D some 18 years later. This association persists after 
adjustment for potential confounders as well as baseline HbA1, HDL-c and smoking history, 
which were also associated with these PWA measures.  
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3.2 INTRODUCTION 
Cardiovascular disease (CVD) occurs with greater frequency and at an earlier age in those with 
diabetes mellitus, a finding particularly striking in women [58]. These observations are 
especially true for those with type 1 diabetes (T1D), in whom coronary artery disease (CAD) is 
increased tenfold or greater [62, 63]. Much of what is understood regarding risk for CAD in T1D 
revolves around presence and severity of atherosclerosis and its risk factors 
(dyslipidemia/hyperlipidemia). Blood flow dynamics and arteriosclerosis, or arterial stiffening, 
indices of which are measured in a variety of ways [165], are also important risk factors for 
cardiovascular events and mortality [4, 166-168]. Interestingly, in case-control studies, arterial 
stiffness indices are shown to be increased in T1D [9, 10, 169]. Indices of arterial stiffness can be 
measured noninvasively with pulse waveform analysis (PWA)[163, 170, 171],[172] using 
applanation tonometry (external application of a micromanometer-tipped probe over a peripheral 
artery) [159, 173]. Via PWA, a variety of indices and hemodynamic parameters can be derived 
including augmentation pressure (AP) and augmentation index (AIx), both of which provide 
information about the effects of early wave reflection on central blood pressure, as well as 
subendocardial viability ratio (SEVR), the ratio of the area under the time-pressure curve during 
diastole (an estimate of myocardial perfusion) to the area under the curve during systole (an 
estimate of cardiac workload) and an indicator of potential for myocardial ischemia [174].  
Currently, few data are available concerning risk factors for increased arterial stiffness in 
T1D. Autonomic neuropathy (AN) is a T1D complication that predicts cardiovascular events and 
mortality [175]. The autonomic nervous system is responsible for regulating heart rate and 
vascular tone and therefore may contribute to increased arterial stiffness in T1D. Therefore the 
aim of the present study is to examine the association between autonomic nerve function and 
36 
indices of arterial stiffness, AIx and AP, and with SEVR, an estimate of myocardial perfusion, in 
a T1D population.  
3.3 METHODS 
Participants in the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study, an 18-
year prospective investigation of patients with childhood-onset (age <17 years) T1D were 
selected for study. Individuals were either diagnosed or seen within 1 year of diagnosis at 
Children’s Hospital of Pittsburgh between 1950 and 1980 and were on insulin therapy at initial 
discharge [27, 176]. Initial evaluation in the EDC study occurred between 1986 and 1988 then 
followed by biennially. Full examination at 18 years included PWA. The EDC Study 
population has been shown to be epidemiologically representative of the T1D population of 
Allegheny County, Pennsylvania [177]. The study protocol was approved by The University 
of Pittsburgh Institutional Review Board.  
Physical activity was assessed using a survey previously described [178]. A summary 
estimate of energy expenditure was derived and expressed as kcal/min.  Self-reported alcohol 
consumption (average drinks/week), current and ever smoker status (at least 100 cigarettes 
during lifetime) and medication (coded according to ATC/DDD codes) use were obtained. 
Medications of interest in these analyses were those potentially effecting pulse wave reflection 
indices (i.e. angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor blockers 
(ARBs), calcium channel blockers (CCBs), beta-blockers (BB) and nitrates [179].  
Systolic and diastolic blood pressures (SBP and DBP) were measured using a random 
zero sphygmomanometer, according to the Hypertension Detection and Follow-Up Program 
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protocol, after a 5-minute rest [180].  Hypertension (HTN) was defined as blood pressure of 
≥130/80 mmHg or the use of antihypertensive medication for the purpose of lowering blood 
pressure.  Height was measured in cm and weight in kg. BMI was calculated from height and 
weight and expressed as kg/m2. Waist and hip circumferences were measured 2 times, and a 
third if the first two were not within 0.5 cm of one another. The means of waist and of hip 
measurements were used to calculate waist-to-hip ratio (WHR). Total cholesterol (TC) levels 
were measured enzymatically [181, 182]. High-density lipoprotein cholesterol (HDL-c) levels 
were determined by means of a precipitation technique (heparin and manganese chloride) with 
modification [183] of the Lipid Research Clinics method [184]. Non-HDL cholesterol was 
calculated by subtracting HDL-c cholesterol level from TC level.  
 Complete blood counts (CBC) were determined using the Coulter S-Plus IV. Urinary 
creatinine concentrations were measured using an Ekachem 400 analyzer (Eastman Kodak Co, 
Rochester, NY).  For the first 18 months, blood samples were analyzed for hemoglobin A1 
(HbA1; microcolumn cation-exchange; Isolab, Akron, OH). For the remainder of the baseline 
clinic visits, automated high-performance liquid chromatography (Diamat; Bio-Rad, Hercules, 
CA) was performed. Serum creatinine was assayed using an Ectachem 400 Analyzer (Eastman 
Kodak Co, Rochester, NY)[185] and urinary albumin was measured by immunonephelometry 
[186, 187]. Albumin excretion rates (AER) were calculated using urinary albumin levels from at 
least 2 validated timed sample collections. Heart rate response to deep breathing, expiration-
inspiration ratio (E/I) was used to test for autonomic neuropathy (AN). An E/I <1.1 was 
considered abnormal [188].  
 Certain medications are known to affect measures of arterial stiffness including 
angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), beta 
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blockers, calcium channel blockers and nitrates. In order to account for the potential confounding 
effect of use of these medications a “Pulse Wave Drug” (PWD) variable was created.  PWD use 
was coded as 0 no use of these medications was reported and 1 if use of one or more of the 
medications were used.  
Of those EDC study participants examined at baseline (n=658), 22.7% (n=150) had died 
by the 18-year follow-up (November 2004 – November 2006), 78 had moved out of area, 101 
declined exam, 19 were lost to follow-up leaving 318 eligible for 18 year exam, 309 for which 
data was available for this analysis. Pulse waveform analysis (PWA) testing began part way 
through the 18-year examination period (January 2006), after which 189 subjects were seen and 
144 (76%) had PWA. The PWA population thus 144 men and women in attendance at the 18-
year follow-up clinic visit after January 1 2006.  Aortic augmentation index (AIx), aortic 
augmentation pressure (AP) and subendocardial viability ratio (SEVR) were derived using 
waveforms measured at the radial artery using the SphygmoCor Vx version 7.01 (AtCor 
Medical, Sydney, Australia). In brief, a high-fidelity micromanometer with a frequency response 
of >2 kHz (Millar Instruments, Houston, TX) was placed on the right radial artery, and gentle 
pressure was applied until a consistent waveform was produced. After at least 20 sequential 
waveforms had been acquired, measurement was stopped. Central pressure values were 
estimated from radial measurements using the software’s mathematical transfer function [159, 
189]; the accuracy and reliability of which have been validated [163, 172]. The pressure wave 
created by left ventricular contraction propagates forward until meeting sites of resistance which 
reflect the wave backward. Stiffer artery walls result in earlier wave reflection [168, 171]. When 
the reflected wave returns during systole rather than diastole, systolic pressure is increased or 
“augmented”.  Augmentation pressure (AP) is a measure of how much the early reflected wave 
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contributes to central systolic pressure. Augmentation index (AIx) represents the level of 
augmentation measured and is expressed as a percentage of the pulse pressure (AIx = AP/PP). 
Heart rate is inversely associated with AIx and AP [121]. Subendocardial viability ratio (SEVR), 
the ratio of the diastolic area under the curve (AUC) of an arterial pulse wave to the systolic-
AUC [190, 191] is a ratio of myocardial perfusion (as coronary artery perfusion takes place 
primarily during diastole) to myocardial contraction, and is a tonometric, non-invasive measure 
of myocardial perfusion relative to cardiac workload. The SphygmoCor device provides a quality 
index (QI) which represents reproducibility of the waveform. If PWA produced results with a 
QI<80 the measure was repeated. Measures with a QI ≥ 80 were included in this study. 
Distributional characteristics and normality of all variables were assessed. Student’s t-test 
and One-Way ANOVA were used to compare continuous normally distributed variables between 
groups while Mann-Whitney U and Kruskal-Wallis tests were used for variables not meeting the 
parametric assumptions (AP, TG, serum creatinine, AER, WBC). The χ2 test was used to 
compare categorical variables between groups. 
Pearson’s and Spearman’s correlations were used for bivariate correlations for normal 
and non-normal variables, respectively. Linear regression models were created for AIx, AP and 
SEVR, for which all categorical variables (medication use, smoking history) were coded as 
either 0 or 1, 1 representing the use/presence. Sex was also categorized as 0 (males) and 1 
(female).  All continuous variables were standardized to the population prior to multivarate 
analyses. Linear regression for augmentation pressure used natural logarithmically transformed 
AP (LnAP) as model residuals were not normally distributed. Forward regression was completed 
in a stepwise manner, for each PWA measure with baseline variables adjusting for concurrent 
potential confounders (even if not statistically significant). All statistical analyses were 
40 
conducted using SPSS 15.0 for Windows (SPSS, Chicago, IL).  Due to the limited sample size 
factors with p-values <0.10 are reported.  
3.4 RESULTS 
Characteristics of the PWA study population (n=144, 46.6%) and the remaining EDC population 
examined at the 18 year follow-up (n=165, 53.4%) are listed in Table 3.  The mean±SD age and 
diabetes duration for the PWA population at baseline were 25.9±7.38 and 17.6±6.70, 
respectively, which did not significantly differ from the remaining EDC population. The only 
baseline factor that differed significantly between PWA participants and non-participants was 
mean heart rate (76.0±12.3 vs. 73.1±11.1; p=.04). At follow-up, those with PWA measures still 
had significantly higher mean heart rate compared to non-participants as well as lower mean 
WHR and mean AER (data not shown).  PWA participants also had a borderline significantly 
greater percentage of reported current smokers (15% vs. 8%, p=0.05) but not ever smokers 
(40.0% vs. 31.7%, p=.13). They also had greater mean±SD alcoholic drinks/week (2.6±6.1 vs. 
1.81±5.22, p=0.09) than non-PWA EDC participants.   
 AIx and AP were highly correlated (r=0.897 p<.001). Both factors were also significantly 
correlated with height, HR and age (p<0.01). SEVR was not significantly correlated with AIx 
(r=-.058, p=.49), but was negatively correlated with AP (r=-.214; p=.01). SEVR was also 
significantly, negatively correlated with age (r=-.292, p<0.001), heart rate (r= -0.665, p<.001), 
and positively with height (r= 0.229, p<.01) in the PWA population. AIx and AP remained 
significantly correlated with height after adjustment for sex, but SEVR did not.  
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 Unadjusted correlations between PWA measures and baseline variables are described in 
Table 4. Baseline E/I ratio, heart rate, energy expenditure in sports activities were all negatively 
associated with Aix and AP and positively associated with SEVR.  Non-HDL-c was positively 
associated with AP, but not AIx and negatively with SEVR as was AER. BMI was related only 
to AIx, in a positive direction. AIx and AP were higher in females and SEVR lower compared to 
males (Table 4). This was also the case between those with a history of smoking compared to 
those without. 
Ninety (62.5%) of the 144 PWA study participants reported PWD use. Most, 88.9% 
(n=80), were using an ACEI and/or ARB’s. Of the 16 participants taking beta blockers, 10 
(62.5%) were also taking ACEI/ARBs; 13 of the 18 reporting calcium channel blocker use and 4 
of the 5 participants reporting nitrate use were also taking ACEI/ARB.   
In multivariate analyses relating baseline PWA measures while adjusting for concurrent 
potential confounders (age, heart rate, height, sex, PWD use), lower E/I ratio and HDL-c and 
history of smoking were associated with increased follow-up AIx and Ln(AP) (Table 5). Higher 
baseline HbA1 was also associated with increased AP. The baseline factors associated with 
decreased SEVR were lower E/I ratio, higher HbA1 and having a smoking history.  When 
models were adjusted for ACEI/ARB use instead of PWD use, results were similar. However, 
ACEI/ARB use was more significantly related to PWA measures than was the more inclusive 
PWD use variable (data not shown).  
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3.5 DISCUSSION 
The main outcome of interest of this study is that baseline autonomic neuropathy, as measured 
by E/I ratio, is a potent predictor of arterial stiffness, as measured by both augmentation index 
and augmentation pressure, and of reduced estimated myocardial perfusion, as measured by 
SEVR, in childhood onset Type 1 diabetes, some 18 years later. Along with autonomic 
neuropathy, know cardiovascular risk factors such as reduced HDL-c and cigarette smoking were 
also predictive of increased stiffness indices AIx and AP. Poorer glycemic control (higher 
baseline HbA1) in this T1D population was also associated with higher AP and with reduced 
SEVR.  
The current results indicate that autonomic neuropathy may exert a pathophysiological 
role in the development of arterial stiffening. E/I ratio was predictive, multivariately, of AIx and 
LnAP.  Our finding that E/I and arterial stiffness indices are linked is consistent with the finding 
by Ahlgren et al. that there was a significant correlation between E/I ratio and aortic stiffness, 
measured as aortic distensibility using ultrasonography, in females with T1D [192]. In our sex 
adjusted analyses, E/I was related to all three PWA measures. In sex-stratified analyses (data not 
shown), E/I remained significantly associated with AP and SEVR in females but not in males. 
However, due to the limited sample size, stratified analyses are not conclusive. In T1D, diabetic 
autonomic neuropathy is associated with increased all-cause mortality [193] and specifically 
cardiovascular fatality as well as non-fatal cardiovascular events, especially in those with 
nephropathy [175]. Cardiovascular autonomic neuropathy (CAN) is shown to be associated with 
left ventricular hypertrophy and diastolic dysfunction in T1D [194]. As arterial stiffness indices 
are shown to contribute to left ventricular diastolic dysfunction [195], arterial stiffness may be a 
link between AN and cardiovascular disease.  T1D patients without nephropathy, retinopathy or 
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neuropathy have preserved vascular function [196, 197] which suggests an intimate relationship 
between vascular dysfunction and these complications.   
Lower HDL-c, a traditional cardiovascular risk factor, but not higher non-HDL-c, was 
independently predictive of AIx and LnAP. In a study of healthy subjects, Duprez et al. showed 
that low HDL-c was significantly correlated to AP and AIx in women, but not in men [198]. 
However, the study examined only univariate correlations. The results of the present study 
showed that baseline HDL-c was correlated with both AIx and LnAP in partial correlations and 
in multivariate, sex-adjusted models. In sex-stratified analyses, lower HDL-c remained 
significantly associated with higher AIx and higher AP in women and with higher AP in men.  
Having a history of smoking was significantly associated with all three outcomes.  This 
finding is not surprising as cigarette smoking is an established cardiovascular disease risk factors 
[199] and is known to be associated with arterial stiffness indices, particularly in those with 
hypertension [200].  A higher baseline HbA1 was associated with increased AP and decreased 
SEVR in the present study. This is consistent with the notion that the formation of advanced 
glycation end products (AGEs) is one of the primary mechanisms thought to be involved arterial 
stiffening, especially in those with diabetes. Arterial wall exposure to AGEs can cause cross-
linking of collagen molecules which in turn reduces arterial elasticity [109]. Advanced glycation 
end-products (AGEs) are shown to be associated with increased arterial AIx in persons with 
hypertension [201]. Schram et al showed that AGEs, pentosidine, Nepsilon-
(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine, were all significantly associated with 
increased pulse pressure in those with T1D in a cross-sectional analysis, although HbA1c was 
not [135]. In our study, concurrent HbA1c also was not significantly associated with PWA 
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measures (data not shown). Baseline HbA1 level may better represent early exposure to 
hyperglycemia leading to AGE exposure.  
Many of the factors associated with augmentation index were also associated with 
augmentation pressure in this study. This is not surprising as AIx is merely AP/PP x 100. AP is 
the measure of contribution that the wave reflection makes to the systolic arterial pressure, and it 
is obtained by measuring the reflected wave coming from the periphery to the centre.  As the 
reflected wave returns earlier in the cardiac cycle, there is a disproportionate rise in SBP and 
therefore an increase in PP. It has been shown that AIx increases with age in healthy population 
until approximately 55 years of age, but that AP steadily increases with age without reaching a 
plateau [202]. The difference is due to the positive association between PP and age.  At a certain 
point it seems that AP is a better representation of vascular aging than AIx because widening 
pulse pressures result in lower AIx. This may be the case in those with T1D as its presence is 
associated with accelerated vascular aging [153]. As poorer glycemic control is associated with 
increased PP [135] this may explain why baseline HbA1 was associated, multivariately, with AP 
but not with AIx.  
This study is not without limitations. For one, the limited sample size; in an attempt to 
make up for this limitation, p-values ≤ 0.10 were represented. Another limitation is the lack of 
pulse wave analysis measurement at baseline. Due to this, the factors found significant in this 
study can only be considered potential predictors of the arterial stiffness indices measured, and 
should be studied further in prospective study of T1D populations. Blood glucose level has been 
shown to acutely affect arterial stiffness measures in T1D[157] however, blood glucose 
measurements at the time of measurement were not taken in this study.  Another thing that could 
be considered a potential limitation is that pulse wave analysis was used and not pulse wave 
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velocity, the accepted gold standard [101]. PWV is considered the gold-standard because it is 
based on direct measurements of parameters linked to regional arterial stiffness and carotid-
femoral PWA specifically, is considered clinically relevant as this measures pressure and 
stiffness within the aorta and large arteries which are closest to and most influential on the heart 
[101].  However, pulse wave analysis is an easy to implement, quick, well-tolerated and reliable 
technique that can be reasonably implemented in a clinical setting. Central pressure measures 
derived from PWA are correlated with PWV measures, are already shown to be altered in the 
presence of T1D [9, 169] are associated with adverse outcomes [112, 117]. 
Another limitation is that this population is essentially a survivor population and that 
those who were unable to attend or deceased at the 18 year clinic visit may represent those with 
greatest risk for complications and possibly those most affected by increased arterial stiffness. 
Also, compared to those at the 18-year follow-up but without PWA measures, the subpopulation 
in the present study had significantly lower follow-up AER measures and waist-to-hip ratio and 
therefore may represent a healthier segment of our T1D population (data not shown). However, 
these limitations are more likely to hinder finding significant relationships between baseline 
factors and follow-up PWA measures than demonstrate false relationships.  
 This is the first study to examine multiple potential risk factors for arterial stiffness in a 
type 1 population. The findings of this study are significant in that it has found that certain 
modifiable and/or treatable risk factors, such as cigarette smoking, poor glycemic control, and 
low HDL-c levels, are associated with increase indices of arterial stiffness and lower estimated 
myocardial perfusion later in life in T1D. The results of this study also confirm that that the use 
of anti-hypertensive medications, specifically ACEI/ARB, are associated with lower arterial 
stiffness indices, but also shows that they do not necessarily improved coronary artery perfusion. 
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Early testing and treatment for autonomic neuropathy may also be effective in reducing arterial 
stiffness and in turn cardiovascular morbidity and mortality in those with T1D.   
In summary, this study demonstrates that, along with traditional cardiovascular risk 
factors associated with structural changes in arteries (low HDL, smoking, poor glycemic 
control), historical measurements of E/I ratio, a measure of autonomic neuropathy, are predictive 
of increased augmentation index and augmentation pressure (indices of arterial stiffness) and 
lower subendocardial viability ratio (an estimate of myocardial perfusion) in T1D. These results 
suggest that autonomic neuropathy plays role in development of arterial stiffness and may be the 
potential link between these factors and cardiovascular events in type 1 diabetes.  
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Table 3.  Baseline characteristics of The Pittsburgh EDC Study Pulse Wave Analysis population compared to the 
remaining 18-year follow-up participants 
 PWA  
Study Population 
N=144 
Remaining 18-year  
EDC Populationa 
N=165 
Female (%) 50.7 (73) 52.1 
Age (years) 25.9±7.38 26.7±7.50 
Diabetes Duration (years) 17.6±6.70 18.7±7.34 
Systolic Blood Pressure (mmHg) 111.4±13.1 110.2±12.5 
Diastolic Blood Pressure (mmHg) 71.8±10.1 70.6±10.1 
Hypertension (%) 22.2 19.4 
Heart Rate (bpm) 76.0±12.3 73.1±11.1** 
HbA1 (%) 10.1±1.69 10.1±1.71 
Non-HDL-c (mg/dL) 127.2±39.9 128.1±36.7 
HDL-c (mg/dL) 54.0±11.0 55.6±14.1 
Triglyceride (mg/dL) 94.1±81.9 90.3±53.2 
Waist-to-Hip Ratio 0.82±0.07 0.82±0.07 
Body Mass Index (kg/m2) 23.5±3.10 23.4±3.37 
Serum Creatinine (mg/dL) 0.90±0.36 0.93±0.78 
AER (μg/min) 238.5±653.8 229.0±734.3 
Expiration-to-Inspiration Ratio 1.14±0.12 1.13±0.12 
WBC (x10-9/L) 6.25±1.76 6.20±1.64 
Energy Expenditure (kcal/wk) 930.3±1324.9 1112.6±1626.4 
Ever Smoker (%) 34.5 28.0 
Prevalent CAD (%) 4.2 3.6 
Abbreviations: Epidemiology of Diabetes Complications, EDC; high-density lipoprotein,  
HDL-c, kilocalories, KCAL; albumin excretion rate, AER; white blood cell count, WBC. 
Data presented mean±SD or %.  
aThose included in PWA study compared to the remaining Pittsburgh EDC study population at 
the 18-year follow-up; continuous variables using t-test or Mann-Whitney U for non-parametric 
variables (E/I Ratio, WBC, AER, Energy Expenditure, Serum Creatinine, Fibrinogen) and 
categorical using χ2. 
** p<0.05 
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Table 4. Correlations (or mean±SDa) between baseline factors and follow-up pulse wave analysis measures 
(augmentation index, augmentation pressure and subendocardial viability ratio) 
 AIx AP SEVR 
Expiration:Inspiration Ratio  -.18** -.32**** .47**** 
Heart Rate (beats per minute) -.20** -.16* -.44**** 
Systolic Blood Pressure (mmHg) -.09 -.03 -.11 
Diastolic Blood Pressure (mmHg) -.00 -.01 -.03 
HbA1 (%) .02 .06 -.12 
NonHDL-c (mg/dl) .11 .153* -.164* 
HDL-c (mg/dl) .10 .05 .03 
Waist-to-Hip Ratio -.04 .02 .05 
Body Mass Index (kg/m2) .19** .11 -.12 
Albumin Excretion Rate (µg/min) .10 .19** -.22*** 
Serum Creatinine .11 .11 -.05 
White Blood Cell Count .11 .12 -.07 
Energy Expenditure -.28**** -.29**** .20** 
Males (n=71)a 19.4±11.5 7.66±6.36 149.7±29.8 
Females (n=73)a,b 26.5±9.18 10.4±6.42 135.8±31.2 
Never Smoker (n=93)a 22.0±11.5 8.42±6.85 145.8±31.1 
Ever Smoker (n=49)a,c 25.3±9.59* 10.3±5.71 135.1±30.6 
AIx, Augmentation Index; AP, Augmentation Pressure; SEVR, subendocardial viability ratio. 
*p<.10,**p<.05,***p<.01,****p<.001. 
a mean ± standard deviation of AIx, AP and SEVR for categorical variables.  
b males compared to females: AIx: p<.001; AP: p=.003; SEVR: p=.01. 
c never smokers compared to ever smokers: AIx: p=.09; AP: p=.01; SEVR: p=.05. 
Pearson’s correlations used for all normally distributed variables and comparisons with 
categorical (sex and ever smoker status) variables. Spearman’s correlations for correlations of 
any non-normal variables (AP, Albumin Excretion Rate, Energy Expenditure, White Blood Cell 
Count, Alcohol Intake) 
 
Table 5. Baseline predictors of AIx, LnAP and SEVR in multivariate linear regression analysis post potential confounder adjustment 
 AIx Ln(AP) SEVR 
 β Se p β se p β se p 
Concurrent Age .187 .077 .02 .068 .013 <.001 -.293 .067 <.001 
Concurrent HR -.434 .066 <.001 -.063 .011 <.001 -.674 .055 <.001 
Female Sex .494 .194 .01 .073 .032 .03 -.377 .150 <.001 
Concurrent Height -.322 .094 .001 -.043 .015 .01 -- -- -- 
PWD Use -.289 .142 .04 -.039 .026 .05 .077 .118 .52 
 Δr2 β se p Δr2 β Se p Δr2 β se p 
HDL-c .054 -.242 .071 .001 .053 -.046 .013 .001 -- -- -- -- 
E/I Ratio .023 -.171 .081 .04 .035 -.026 .015 .05 .009 .126 .067 .06 
Ever Smoker .013 .247 .136 .07 .017 .046 .022 .04 .046 -.410 .108 <.001 
HbA1 -- -- -- -- .019 .026 .011 .02 .022 -.129 .055 .02 
MODEL .494  <.001 .527  <.001 .679  <.001 
Variables are standardized to the population (variable-mean)/standard deviation. 
Base models with concurrent age, heart rate (HR), height, sex and use of medications with potential affect on pulse wave analysis 
measures (PWD use: Angiotensin Converting Enzyme Inhibitors, Angiotensin II Receptor Blocker, Calcium Channel Blocker, 
Beta Blocker, and/or Nitrate use). 
Baseline variables available for forward regression: systolic blood pressure, diastolic blood pressure, NonHDL-c, HDL-c, white 
blood cell count, albumin excretion rate, serum creatinineHbA1, body mass index, waist-to-hip ratio, Energy expenditure in sports 
at baseline, Expiration-to-Inspiration Ratio (E/I), serum creatinine.  
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 4.1 ABSTRACT 
BACKGROUND: Type 1 Diabetes (T1D) is associated with a high risk for and mortality from 
premature coronary artery disease (CAD). Coronary artery calcification (CAC), a subclinical 
marker of CAD, is shown to predict CAD events as is lower extremity arterial disease (LEAD). 
Pulse Wave Analysis (PWA) arterial stiffness indices are associated with cardiovascular disease 
(CVD) risk factors and outcomes in various populations. Availability of data regarding the 
relationship between these measures and CVD in T1D is limited. 
METHODS: PWA was performed using the Sphygmocor Px device on 144 participants in The 
Pittsburgh EDC Study of childhood onset T1D.  The cross-sectional association between arterial 
stiffness indices augmentation index (AIx) and augmentation pressure (AP) and estimated 
myocardial perfusion via subendocardial viability ratio (SEVR), and prevalent CAD, electron 
beam computed tomography measured CAC and  low (<0.90) ankle-brachial index (ABI). 
RESULTS: Higher AP (but not AIx) and lower SEVR were univariately associated with low 
ABI, prevalent CAD and high CAC score. AP and SEVR’s association with CAD and CAC did 
not remain significant, multivariately, after the addition of age. After exclusion of nitrate use, 
higher AP was significantly associated with increased risk for hard CAD events over brachial 
blood pressure measures and age, multivariately and lower SEVR was associated with high 
CAC. Lower SEVR was also associated with low ABI, multivariately. 
CONCLUSIONS: Central pressure augmentation and decreased myocardial perfusion are 
associated with the presence of low ABI in T1D, consistent with the physiologic process 
underlying the development of early return of the reflected pulse wave.  These factors are also 
altered in the presence CAD however, age (partially reflecting T1D duration in our early onset 
population) remains an important determinant of CAD, including subclinical CAD. Medication 
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 use, in particular nitrates, complicates cross-sectional analyses. Exclusion of nitrate use showed 
that augmentation pressure is in fact associated with hard CAD in T1D and low SEVR with 
CAC.  Prospective studies are needed examine the predictive value of PWA arterial stiffness 
indices in T1D populations 
4.2 INTRODUCTION 
Type 1 diabetes (T1D) is associated with high risk (10-fold or greater) of, and increased 
mortality from, premature coronary artery disease (CAD) [62, 63]. This increased risk is 
especially apparent in women with T1D, virtually eliminating the traditional female advantage 
seen in the absence of diabetes [72, 73]. In T1D, the atherogenic process appears to start earlier 
and occur more rapidly thereby leading to early mortality and morbidity [72, 203] . Traditional 
factors shown to be associated with increased risk for both CAD and with lower extremity 
arterial disease (LEAD), (a type of peripheral vascular disease), in T1D include altered 
lipoprotein metabolism, nephropathy and hypertension [73, 86, 203-205].  Coronary artery 
calcium (CAC) measured using electron beam tomography can be used as an indicator of 
atherosclerotic burden [206], and in those with T1D, CAC has been correlated with CAD [207]. 
Persons with T1D are also at increased risk for LEAD, risk for which is higher in females than in 
males with T1D [205]. Vascular stiffness can be measured in a variety of ways. One way is via 
pulse wave analysis to measure the pulse waveform and timing of reflected waves. Increased 
arterial stiffness increases the velocity of forward blood flow in arteries as well as that of 
reflected waves. Increased blood flow velocity and earlier reflection of pulse waves results in 
earlier arrival (within the cardiac cycle) of reflected waves to the aorta causing central pressure 
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 augmentation. This augmentation pressure (AP) can be measured non-invasively using 
applanation tonomentry and quantified as augmentation index (AIx) which is the AP expressed 
as a percentage of the aortic pulse pressure (PP) (AIx=AP/PP x100). The subendocardial 
viability ratio (SEVR), also known as The Buckberg index, can also be determined using radial 
applanation tonometry. SEVR is an estimate of myocardial perfusion and a measure of the 
propensity to cardiac ischaemia. It is calculated by dividing the diastolic time-pressure (area 
under the pressure curve) by systolic time-pressure and is expressed as a percentage. AIx, which 
has been shown to be elevated in T1D [9, 169], has also been found to correlate with traditional 
CAD risk factors [131][208, 209], coronary atherosclerosis[210, 211], cardiovascular outcomes 
[117, 212] and extracoronary atherosclerosis in those with CAD [213].   
As arterial stiffness indices such as augmentation pressure, augmentation index and/or 
pulse wave velocity have been associated with both CAD [117, 210, 214], CAC [215, 216] and 
lower ankle-brachial index (ABI), (a measure of LEAD) [213, 217]. Since these relationships 
have yet to be explored in a T1D population, the aim of this study is to examine, cross-
sectionally, the relationships between indices of arterial stiffness and myocardial perfusion as 
measured using applanation tonometry, and prevalent coronary artery disease, coronary artery 
calcification, and low ABI in population with childhood onset type 1 diabetes. 
4.3 METHODS 
Participants in the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study, an 18-
year prospective investigation of patients with childhood-onset (age < 17 years) T1D were 
selected for study. Individuals were diagnosed, or seen within 1 year of diagnosis, at 
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 Children’s Hospital of Pittsburgh between 1950 and 1980 and were on insulin therapy at 
initial discharge [27, 176]. Initial evaluation in the EDC Study occurred between 1986 and 
1988 and biennial reexamination followed for 10 years, followed by a more limited, survey, 
follow-up then another full clinical examination at 18 years. The 18 year examination included 
pulse wave analysis measures via radial applanation tonometry. The EDC Study population 
has been shown to be epidemiologically representative of the type 1 diabetes population of 
Allegheny County, Pennsylvania [177]. The study protocol was approved by The University 
of Pittsburgh Institutional Review Board.  
 Questionnaires concerning demographic, health care, self-care, and medical history 
information were sent to participants prior to clinic examinations. Smoking history (at least 
100 cigarettes in lifetime), current smoker status and medications use were obtained. All 
medications were coded according to ATC/DDD codes. Medications with potential effects on 
pulse wave reflection measures (angiotensin converting enzyme inhibitors (ACEIs), 
angiotensinogen receptor II blockers (ARBs), calcium channel blockers (CCBs), beta-blockers 
(BB) and nitrates) were of particular interest and use of 1 or more of these medications was 
categorized as use of a “pulse wave drug” (PWD). The other type of medication of interest 
were antilipidemic agents.  
During clinic visits, systolic and diastolic blood pressures (SBP and DBP) were 
measured using a random zero sphygmomanometer, according to the Hypertension Detection 
and Follow-Up Program protocol, after a 5-minute rest [180].  Hypertension (HTN) was 
defined as blood pressure of ≥130/80 mmHg or the use of antihypertensive medication for the 
purpose of lowering blood pressure.  Height (in cm) and weight (in kg) were measured and 
BMI calculated and expressed as kg/m2.  Waist and hip circumferences were twice and a third 
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 time if measurements were not within 0.5 cm. The mean of waist measurements and that of 
hip measurements were used to calculate waist-to-hip ratio (WHR).  
Total cholesterol and triglycerides were measured enzymatically [181, 182]. High-
density lipoprotein (HDL) cholesterol level was determined by means of a precipitation 
technique (heparin and manganese chloride) with modification [183] of the Lipid Research 
Clinics method [184]. Non-HDL cholesterol was calculated by subtracting HDL cholesterol 
level from total cholesterol level. Blood samples were analyzed for hemoglobin A1C using the 
DCA 2000 analyzer (Bayer Diagnostics, Tarrytown, NY).  
Soft coronary artery disease was determined as EDC physician-diagnosed angina or 
ischemic electrocardiogram changes (Minnesota codes 1.3, 4.1 to 4.3, 5.1 to 5.3, and 7.1).  
Hard CAD events were defined as myocardial infarction confirmed by Q waves on 
electrocardiogram (Minnesota codes 1.1 or 1.2) or hospital records or angiographic stenosis of 
50% or greater, coronary artery bypass surgery, angioplasty, or ischemic electrocardiogram 
changes (Minnesota codes 1.3, 4.1 to 4.3, 5.1 to 5.3, and 7.1).  During the 10, 16 and 18- year 
follow-up exams, electron beam tomography with a GE-Imatron ultrafast computed 
tomographic scanner (GE-Imatron, San Francisco, California) was used to assess CAC. Scans 
were triggered by electrocardiographic (ECG) signals at 80% of the RR interval and obtained 
in 3-mm contiguous sections of the heart. At year 10, only one CAC score was measured, 
while at years 16 and 18 two CAC scores were used, the means of which were calculated. The 
most recent CAC score (or mean of scores) was selected for the present study.  CAC scores 
were also categorized as 1) None/Mild:  0-99, 2) Moderate: 100-399, 3) Severe : ≥400 for 
univariate and linear trend analyses and as presence of clinically significant CAC (≥100 mm3) 
for multivariate analyses. 
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 Resting ankle-brachial systolic blood pressures were taken in the supine position with a 
Doppler blood-flow detector. The right and left tibialis posterior and dorsalis pedis pressures 
were compared with the arm pressure, and an ankle-to-brachial index (ABI) was calculated 
using the arm pressure measurement taken closest in time to the ankle pressure.  An ankle-
brachial index (ABI) of <0.9 on either side at rest was considered to be evidence of LEAD. An 
ABI of >1.3 was considered as high ABI. A broader definition of LEAD comprised of low 
ABI (<0.9), a history of claudication as determined by the ROSE questionnaire[218] or self-
reported history of amputation for vascular cause.  
Of those EDC study participants examined at baseline (n=658), 22.7% (n=150) had died 
by the 18-year follow-up (November 2004 – November 2006), 78 had moved out of area, 101 
declined exam, 19 were lost to follow-up leaving 318 eligible for 18 year exam, 309 for which 
data was available for this analysis. Pulse waveform analysis (PWA) testing began part way 
through the 18-year examination period (January 2006), after which 189 subjects were seen and 
144 (76%) had PWA. The PWA population thus 144 men and women in attendance at the 18-
year follow-up clinic visit after January 1 2006. Aortic augmentation index (AIx), aortic 
augmentation pressure (AP) and subendocardial viability ratio (SEVR) were derived using 
waveforms measured at the radial artery using the SphygmoCor Vx version 7.01 (AtCor 
Medical, Sydney, Australia). In brief, a high-fidelity micromanometer with a frequency response 
of >2 kHz (Millar Instruments, Houston, TX) was placed on the right radial artery, and gentle 
pressure was applied until a consistent waveform was produced. After at least 20 sequential 
waveforms had been acquired, measurement was stopped. Central pressure values were 
estimated from radial measurements using the software’s mathematical transfer function [159, 
189]; the accuracy and reliability of which have been validated [163, 172]. The pressure wave 
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 created by left ventricular contraction propagates forward until meeting sites of resistance which 
reflect the wave backward. Stiffer artery walls result in earlier wave reflection [168, 171]. When 
the reflected wave returns during systole rather than diastole, systolic pressure is increased or 
“augmented”.  Augmentation pressure (AP) is a measure of how much the early reflected wave 
contributes to central systolic pressure. Augmentation index (AIx) represents the level of 
augmentation measured and is expressed as a percentage of the pulse pressure (AIx = AP/PP). 
Heart rate is inversely associated with AIx and AP [121]. Subendocardial viability ratio (SEVR), 
the ratio of the diastolic area under the curve (AUC) of an arterial pulse wave to the systolic-
AUC [190, 191] is a ratio of myocardial perfusion (as coronary artery perfusion takes place 
primarily during diastole) to myocardial contraction, and is a tonometric, non-invasive measure 
of myocardial perfusion relative to cardiac workload. The SphygmoCor device provides a quality 
index (QI) which represents reproducibility of the waveform. If PWA produced results with a 
QI<80 the measure was repeated. Measures with a QI≥80 were included in this study. 
Distributional characteristics and normality of variables was assessed. Binary 
categorical variables were coded as 0 or 1, including sex for which females were 1. Student’s 
t-test, for parametric, and the Mann-Whitney U test, for variables not meeting the non-
parametric assumptions (augmentation pressure, triglyceride level, albumin excretion rate, 
serum creatinine) were used to compare continuous variables between cases and non-cases. χ-
square test was used to examine the differences in binary categorical variables (i.e.: sex, 
medication use, smoking status), between cases and non-cases.  Pearson’s and Spearman’s 
correlations were used, as appropriate, to univariately compare CAC scores with pulse wave 
reflection measures (AIx, AP, SEVR). CAC scores were also categorized as none/minimal (0-
99), mild/moderate (100-399), and severe (≥400) and PWA measures AIx and SEVR were 
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 compared between groups using one-way ANOVA with the Bonferroni correction. AP, as it 
was non-parametric was compared across CAC categories with the Kruskal-Wallis test. All 
continuous variables were standardized by subtracting the mean and dividing the by their 
standard deviation of the study population. Logistic regression was performed, in a stepwise 
manner, separately for prevalent CAD, low ABI and high CAC score.  
4.4 RESULTS 
Cross-sectional characteristics of the PWA population from the Pittsburgh EDC Study are 
detailed in Table 6, along with sex comparisons.  Although crude comparisons of AIx, AP and 
SEVR showed significant differences between the sexes, height adjusted comparisons did not. 
Males and females were of similar age, diabetes durations, and had similar heart rates, BMI’s, 
HbA1c, WBC, and Non-HDL-c levels and coronary artery calcification scores. Percentage 
with hypertension or with a smoking history also did not significantly differ between males 
and females. However, males did have significantly higher SBP and DBP, lower HDLc, and 
greater waist-to-hip. Overall, 22.9% (n=33) of the population had prevalent CAD (soft or hard 
events), 12.5% (n=18) with a history of hard and 10.4% (n=15) with a history of soft events.  
The percentage of males with any type of CAD was higher than in females, but this was not 
statistically significant (28.2% vs. 17.8%). However, the percentage of hard events was 
significantly higher in males compared to females (18.3% vs. 6.8%, p=.04). CAC scores were 
available for 138 (68 males, 70 females) of the 144 PWA participants. Fifty (34.7% of those 
with CAC scores) of the participants had a CAC score ≥100 mm3. The percentage of females 
with CAC score ≥100 mm3 did not significantly differ from males (32.9% vs. 36.6%, p=.63). 
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 Sixteen participants (11.1%) had an ABI <0.90 and 29 (20.1%) had a high ABI.  Presence of 
low ABI differed by sex as 11 (68.8%) of the 16 cases were female, however this difference 
was not statistically significant (p=.13). Presence of high ABI also differed by sex with males 
representing 20 (71.4%) of the 28; this did reach statistical significance at p=.006. 
Table 7 shows the rate of medication use by CAD status. Those with prevalent CAD of 
any type were more likely to be taking a drug with potential effects on PWA measures (78.8% 
vs 57.7%). ACEI/ARB medication use was fairly prevalent throughout the study population 
and did not significantly differ between those with and without CAD.  A greater percentage of 
those with hard CAD reported use of every type of PWD medication that did those with soft 
CAD: ACEI/ARB – 72.2% vs. 40.0%, p=.06; beta-blocker – 33.3% vs. 26.7%, p=.68; calcium 
channel blocker – 27.8%, p=.94; nitrates – 22.2% vs. 6.7%, p=.22. Eleven of those with hard 
CAD reported use of 2 or PWD medications compared to only 3 of those with soft CAD.  
4.4.1 Pulse Wave Analysis Measures and Coronary Artery Disease 
Augmentation index showed no significant univariate associations with any cardiovascular 
outcome (Figure 1). Univariately, lower SEVR was associated with any and soft CAD and 
with increasing CAC score category but not significantly with hard CAD (Table 7 and Figure 
2). Augmentation pressure, although higher in cases of all outcomes (Figure 3), was borderline 
significant when comparing any CAD to non-cases and with increasing CAC category but was 
not significant by CAD type (Table 8).  
 In multivariate logistic regression for any type of CAD, per standardized unit increase in 
AP there was an associated 87% increased risk (OR=1.87; 95%CI: 1.17-3.00; p=.009) for CAD 
in models adjusted for potential confounders (height, heart rate, PWD use). When allowing for 
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 other variables associated with CAD to enter models, age enters and eliminates the significant 
association between AP and prevalent CAD.  Multivariate models for specific CAD type showed 
a similar occurrence for soft CAD (2.5 times risk for CAD per standard unit increase of AP) but 
no significant association between AP and hard CAD even in the model adjusted only for 
potential confounders (data not shown). Multivariate models with SEVR also showed similar 
results for CAD; per standard unit decrease in SEVR there was a 40% increased risk of any CAD 
(p=.07), a 45% increased risk for soft CAD (p=.009) but no significant association with hard 
CAD (p=.77) in confounder adjusted models. The addition of age to multivariate models again 
diminished the statistical significance of the SEVR-CAD relationship.  Due to the potential 
confounding affect of PWD use, multivariate models were performed after excluding each of the 
PWD except for ACEI/ARB use as the majority of participants (60%) reported its use and use 
was not significantly different between CAD cases (57.6%) and non-cases (55.5%). All of the 
models produced results similar to those already discussed except for those which excluded 
nitrate use. Higher AP (OR=2.57; 95%CI:1.03-6.42) was significantly related to hard CAD, 
multivariately, when those taking nitrate medication (n=4) were excluded (Table 8). AP actually 
entered multivariate the model preferentially over brachial measures of systolic and diastolic 
blood pressure as well as over age. Results were similar when diabetes duration was available 
instead of age. Without the availability of AP, age and sex are the major determinants of hard 
CAD in this population. A univariate comparison shows that in those using nitrate (n=5) 
medications, AP is lower (8.80 ± 10.2) than in those not (9.05 ± 6.42). SEVR was still not 
significantly associated, multivariately, with hard CAD when those with nitrate use were 
excluded, but was associated with having high CAC score (Table 9).  
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 Multivariate models for high (≥100 mm3) CAC score were similar to those for clinical 
CAD. AP was borderline significant (OR=1.55; 95%CI: 0.96-2.49; p=.07) in confounder 
adjusted models with entrance of age having the same effect on the relationship. AP models 
adjusted for prevalent CAD showed no significant association between AP and high CAD. 
SEVR was significantly associated with having a high CAC score in confounder adjusted models 
(OR=0.46; 95%CI: 0.26-0.81) with age reducing the statistical significance (OR=0.61; 
95%CI:0.33-1.13; p=.12). CAD adjustment did not significantly alter SEVR models for high 
CAC.  
4.4.2 Pulse Wave Analysis Measures and Ankle-Brachial Index 
Cross-sectional characteristics of the PWA population by ABI category are described in Table 
10. AIx was not significantly different across ABI categories (Table 10 and Figure 1).  
Univariately, AP (p=.08) and SEVR (p=.07) were borderline significantly different by ABI 
category. The most noticeable difference in AP and SEVR was in those with low ABI (Figures 3 
and 2, respectively). Other factors that differed across ABI category were age and diabetes 
duration (those with low ABI being the oldest and having the longest duration) and diastolic 
blood pressure (again lowest in those with low ABI). Waist-to-hip ratio was also borderline 
significantly different by ABI category with the normal group having the lowest WHR. 
Medication use was not statistically different by ABI category, however, a greater percentage 
(81.3%) of those with low ABI were on at least one of the PWD medications.  
 Multivariate models for Low ABI, excluding those with high ABI showed that the AP 
confounder adjusted model, per standardized unit increase in AP, there was a 66% increase risk 
for low ABI (OR=1.66; 95%CI: 0.95-2.90; p=.08). However, when adjusted for age, the 
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 association between AP and low ABI was not significant (Table 11a). SEVR, however, was 
significantly associated with low ABI and preferentially entered heart rate adjusted multivariate 
models over brachially measured systolic and diastolic blood pressure (Table 11b). PWD use 
was not significantly associated with low ABI and did not significantly alter models when 
adjusted for. When a broader definition of lower extremity arterial disease was used (including 
claudication and/or amputation), PWA measures were not significantly associated with presence 
of LEAD multivariately.  
4.5 DISCUSSION 
This study found that augmentation pressure, measured non-invasively using radial 
applanation tonometry, is significantly associated with prevalent coronary artery disease in 
T1D. It was specifically associated with hard CAD, definition for which comprises of 
myocardial infarction, a coronary blockage of at least 50% or history of revascularization 
(coronary artery bypass graph or angioplasty), when use of nitrate medications (n=4 hard 
CAD cases) was excluded. We also found that lower estimated myocardial perfusion, SEVR, 
is associated with presence of high CAC (≥100), again when those reporting nitrate use were 
excluded. This was the case even when adjusting for age and prevalent hard CAD. Another 
finding was that AP was higher in those with low ABI and remained statistically significant 
until the model was adjusted for prevalent CAD. However, reduced SEVR remained 
significantly associated with presence of low ABI, multivariately.  
In some of our multivariate models for CAD and high CAC, the addition of age 
eliminated the significant associations between pulse wave analysis measures and disease.  
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 Age is a major risk factor for CAD as is diabetes duration in T1D[219].  Diabetes duration 
childhood onset in T1D and age are highly correlated, r=.825 in the current study population. 
Diabetes duration has been shown to be closely tied to coronary artery calcification 
progression in T1D in The Pittsburgh EDC Study [220] and age is a known risk factor for 
degree of CAC [221] Arterial stiffness indices are also very much associated with age [108, 
222] and in studies of those with T1D, longer diabetes duration is significantly related to 
higher values of arterial stiffness measures[192, 223]. Given the relationship between age and 
T1D duration, and the association both have with CAD, CAC and arterial stiffness indices, it 
is not entirely surprising that the addition of age to multivariate models for CAD and CAC 
would impact the relationship between the indices and outcomes.  Interestingly, SEVR was 
similar between those with hard CAD compared to those with soft or no CAD even though we 
would expect worse CAD to be associated with lower SEVR. However, this may be due to the 
fact that revascularization is included in the definition of hard CAD in our study. There was 
pervasive use of medications that are known to influence PWA measures in this T1D 
population, particularly in those whom had a history of hard CAD events. Approximately 90% 
of those on PWD’s were on an ACEI or ARB which are shown to be very effective, compared 
to other antihypertensive agents, in reducing values of arterial stiffness indices [224].  
However, since a good proportion of non-cases reported ACEI/ARB use. Use of other 
medications types, such as calcium channel blockers, beta-blockers and nitrates was more 
common among those with CAD, particularly with hard CAD. Therefore, we chose to 
examine the relationship between PWA measures and CAD in their absence. Exclusion of 
calcium channel blockers and beta-blockers each resulted in models similar to those produced 
when they were included. However, it was by excluding those on nitrates, only 4 participants 
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 with hard CAD, that significant changes to multivariate models occurred. Administration of 
exogenous nitrate has been shown to increase vasodilatation, arterial compliance and decrease 
systolic blood pressure [225]. Stokes et al found, in a double-blind randomized cross-over 
study in elderly hypertensives, that administration of isosorbide mononitrate (ISMN) 
decreased not only brachial systolic and diastolic ambulatory blood pressures, but also 
decreased aortic SBP and augmentation pressure [226]. Stokes et al later confirmed the effect 
ISMN on pulse wave analysis measures in a another study which showed ISMN to decreased 
SBP by 16 mmHg, pulse pressure by 13 mmHg and AIx by 4% in a group of older 
hypertensive patients[227]. 
Presence of a low ABI is associated with increased cardiovascular risk [88, 89] and 
cardiovascular and all-cause mortality risk in T1D[228]. Previous studies have shown 
significant association between AIx and ABI in multivariate analyses [213, 217]. While our 
findings show no significant relationship between low ABI and AIx in our T1D population, 
we did find a relationship with augmentation pressure and SEVR.  AIx is the expression of 
augmentation pressure as a percentage of pulse pressure and its effectiveness in the 
representation of increased pulse wave reflection and arterial stiffness in older populations has 
been questioned [202]. As there is potentially accelerated vascular aging in those with T1D 
[153], AIx may not be a suitable index of arterial stiffness in this population either.  LEAD is 
due to atherosclerosis in the arteries of leading to or within the legs. It is logical that 
atherosclerotic changes in lower peripheral vessels contributes to earlier reflection of the pulse 
wave and to an increase in central systolic pressure augmentation. The earlier the timing of the 
wave reflection, the greater the AP, the higher the central systolic pressure therefore the 
greater the pressure the heart must pump against. Overtime, this increased pressure leads to a 
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 reduction in diastolic pressure and duration and it is in diastole that coronary perfusion takes 
place. The findings of the current study are consistent with this physiologic process in that 
reduced diastolic pressure leads to impaired coronary perfusion, i.e. lower SEVR. 
 The cross-sectional design of this study is one of its limitations and a potential reason 
that PWA measures were not significantly associated with all CAD outcomes. A prospective 
design using pulse wave analysis measurements to predict CAD events or CAC progression 
within a T1D population may be more effective in elucidating the relationship between arterial 
stiffness indices and these outcomes. Most participants who had CAD or high values of CAC 
reported PWD use, which is to be expected, but is also a limitation of the study.  The use of 
these types of medications may explain the lack of association between PWA measures and 
some of the CVD outcomes. The limited sample size of our study population is another 
limitation as a greater sample may have yielded more significant results. A larger sample sized 
would have also allowed for stratification by medication use, age (younger vs. older) or 
diabetes duration (shorter vs. longer), as well as sex, which may have contributed to a greater 
understanding of associations.   
In summary, augmentation pressure, an index of arterial stiffness, and subendocardial 
viability ratio, an estimate of myocardial perfusion, are associated with hard CAD and high 
CAC, respectively, in our T1D population.  These factors are also associated with presence of 
low ABI, although AP’s association is diminished by age adjustment. This is the first study to 
examine the association pulse wave reflection measures and prevalent cardiovascular disease 
in a Type 1 diabetes population. Pulse waveform analysis is an easy to implement, non-
invasive measure of arterial stiffness indices and further research into the association between 
these indices and disease in T1D is necessary.  
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Table 6. Cross-sectional characteristics, and sex comparisons, of The Pittsburgh EDC Pulse Wave 
Analysis Study Population 
 
 Males Females Total 
Augmentation Index (%)  21.3 (18.6-24.1)a 24.7 (22.0-27.3) 23.0±11.0 
Augmentation Pressure (mmHg) 8.55 (6.86-10.2)a 9.49 (7.83-11.2) 9.03±6.51 
Subendocardial Viability Ratio (%) 143.7 (135.6-151.2)a 140.7 (132.6-148.7) 142.2±31.1 
Age (years) 45.5±7.70 44.0±7.14 44.7±7.43 
Diabetes Duration (years) 37.1±6.37 35.7±7.06 36.4±6.74 
HbA1c (%) 7.52±1.39 7.37±1.36 7.44±1.37 
Systolic Blood Pressure (mmHg) 119.1±16.9 112.2±15.5** 115.6±16.5 
Diastolic Blood Pressure (mmHg) 69.2±8.38 63.9±9.29**** 66.5±9.21 
Heart Rate (bpm) 77.7±13.2 77.45±12.9 77.6±13.0 
Hypertension (% (n)) 23.9 (17) 17.8 (13) 20.8 (30) 
NonHDL-c (mg/dl) 114.5±15.1 113.3±33.3 113.9±32.7 
HDL-c (mg/dl) 52.2±15.1 64.9±16.1**** 59.2±16.6 
Body Mass Index (kg/m2) 26.9±4.45 27.7±5.14 27.3±4.81 
Waist-to-Hip Ratio  0.91±0.07 0.82±0.09**** 0.87±0.9 
Serum Creatinine (mg/dl) 1.21±0.70 0.96±0.29** 1.08±.054 
White Blood Cell Count (mg/dl) 6.49±1.96 6.38±2.07 6.44±2.01 
CAC Score (mm3) 275.6±554.9 227.9±449.9 251.4±503.1 
Ever Smoker (% (n)) 44.3 (31) 36.6 (26) 39.6 (57) 
Any CAD (% (n)) 28.2 (20) 17.8 (13) 22.9 (33) 
Hard CAD (% (n)) 18.3 (13) 6.8 (5)** 12.5 (18) 
Low ABI (% (n)) 7.0 (5) 15.1 (11) 11.1 (16) 
High ABI (% (n)) 31.8 (21) 11.9 (8) 20.1 (29) 
PWD use (% (n)) 69.0 (49) 56.2 (41) 62.5 (90) 
Anti-Lipidemic Med (% (n)) 49.3 (35) 41.7 (30) 45.5 (65) 
Abbreviations: coronary artery disease, CAD; ankle-brachial index, ABI; pulse wave drug use, 
PWD.aheight adjusted mean (95% confidence interval) compared between males and females. 
*p<.10, ** p<.05, ** p<.01, ****<.001.  
 Table 7. Characteristics of CAD cases and non-cases and CAC score category within EDC PWA study population. 
 No CAD Any CAD Soft CAD Hard CAD CAC Score 
     0-99 100-399 ≥400 
n (%) 111 (77.1) 33 (22.9) 15 (10.4) 18 (12.5) 88 (61.1) 24 (16.7) 26 (18.1) 
AIx (%) 22.4±9.82 25.1±14.2 25.0±13.0 25.1±15.5 22.4±10.6 24.0±8.14 24.9±14.4 
AP (mmHg) 8.09±4.67 12.2±10.1* 13.8±10.7 10.8±9.61 7.98±5.83 9.29±4.51 12.4±10.5*b 
SEVR (%) 144.5±32.4 134.2±25.2* 123.7±23.4** 143.0±18.7 147.3±33.0 136.2±29.6 130.6±24.3**b 
Heart Rate (bpm) 77.7±12.5 77.3±14.9 78.4±14.9 76.4±15.3 77.4±13.9 78.2±9.81 76.9±12.2 
Age (years) 43.1±6.61 49.8±7.59**** 51.0±8.29*** 48.9±7.06*** 42.3±6.57 46.3±6.60 51.4±6.24****b
T1D Duration (years) 34.8±5.89 41.3±7.08**** 43.1±8.42*** 39.7±5.54*** 34.4±6.10 38.6±5.55 41.6±6.62****b
Systolic BP (mmHg) 113.6±15.1 122.1±19.6*** 125.9±16.7*** 118.9±21.6 113.4±15.5 117.2±15.4 120.9±14.6*b 
Diastolic BP (mmHg) 67.2±9.05 64.1±9.47* 61.9±9.43** 66.0±9.36 67.6±9.18 65.5±8.10 62.9±10.1*b 
Non-HDL-c (mg/dL) 115.8±34.2 107.5±26.8 111.8±31.0 103.9±23.1 116.6±33.3 101.9±23.5 111.9±32.7 
HDL-c (mg/dL) 59.5±15.9 57.8±18.3 61.3±21.3 54.3±15.0 60.5±16.8 57.0±17.0 57.0±12.9 
HbA1c (%) 7.41±1.46 7.55±1.05 7.61±0.95 7.49±1.15 7.51±1.47 7.30±1.26 7.33±1.17 
Waist-to-Hip Ratio 0.86±0.09 0.91±0.09*** 0.90±0.11* 0.92±0.07*** 0.86±0.09 0.88±0.11 0.91±0.08**b 
BMI (kg/m2) 27.0±4.58 28.7±5.90* 28.8±5.28 28.6±6.52 27.2±4.64 27.6±6.05 27.30±4.01 
S. Creatinine (mg/dL) 1.03±0.32 1.26±0.94 1.06±0.26 1.42±1.24 1.01±0.28 1.11±0.53 1.30±1.00**b 
WBC (x10-9/L) 6.31±2.09 6.89±1.62 * 6.30±1.66 7.38±1.47** 6.20±2.07 6.78±1.98 6.88±1.92 
PWD Use  (% (n)) 57.7 (64) 78.8 (26)** 73.3 (11) 83.3 (15)** 48.9 87.5 88.5**** 
ACEI/ARB  (% (n)) 55.5 (61) 57.6 (19) 40.0 (6) 72.2 (13)a 0.0 4.2 15.4***b 
Beta blocker  (% (n)) 5.5 (6) 30. 3 (10)**** 26.7 (4)** 33.3 (6)*** 46.6 83.3 61.5 ***b 
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Table 7 continued  
 No CAD Any CAD Soft CAD Hard CAD CAC Score 
     0-99 100-399 ≥400 
Calcium Channel  
Blocker (% (n)) 
8.2 (9) 27.3 (18)*** 26.7 (4)* 27.8 (5)** 3.4 29.2 26.9 ****b 
Nitrates  (% (n)) 0.0 (1) 15.2 (5)*** 6.7 (1) 22.2 (4)**** 0.0 4.2 15.4***b 
Abbreviations: Coronary Artery Disease, CAD; Coronary Artery Calcification, CAC; Augmentation Index, AIx; Augmentation 
Pressure AP; Subendocardial Viability Ratio, SEVR; Type 1 Diabetes, T1D; Body Mass Index, BMI; White Blood Cell Count, WBC; 
Angiotensin Converting Enzyme Inhibitor, ACEI; Angiotensin II Receptor Blocker (ARB). CAD cases compared to those without 
CAD. aACEI/ARB use different (p=.06) by CAD type (hard versus soft). bsignificant linear trend. 
*p<.10, ** p<.05, ** p<.01, ****<.001. 
 
 
 
 
 Table 8. Multivariate logistic regression model for hard CAD (myocardial infarction, >50% blockage, 
revascularization) in The Pittsburgh EDC Pulse Wave Analysis study population 
Variable OR 95%CI p 
Female Sex 0.15 0.03-0.74 .02 
Augmentation Pressure 2.34 1.04-5.28 .04 
Heart Rate  1.16 0.58-2.28 .68 
Height 0.85 0.44-1.64 .63 
Excludes those reporting nitrate use (n=4). Odds ratios are per standardized unit.  
Variables available to the model: augmentation pressure, age, brachial systolic blood pressure, 
bracial diastolic blood pressure, waist-to-hip ratio, HDL-c, NonHDL-c, sex, HbA1c, anti-
lipidemic agent use, PWD use, smoking history, albumin excretion rate.   
Model adjusted for potential confounders: heart rate and height 
 
 
 
 
Figure 1. Augmentation Index (mean and standard error) by prevalent coronary artery disease 
(CAD), coronary artery calcification  (CAC) score and ankle-brachial index (ABI) categories in The 
Pittsburgh EDC Pulse Wave Analysis study population 
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Figure 2.  Subendocardial Viability Ratio (mean and standard error) by prevalent coronary artery 
disease (CAD), coronary artery calcification  (CAC) score and ankle-brachial index (ABI) categories in The 
Pittsburgh EDC Pulse Wave Analysis study population 
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Figure 3. Augmentation Pressure (mean and standard error) by prevalent coronary artery disease 
(CAD), coronary artery calcification  (CAC) score and ankle-brachial index (ABI) categories in The 
Pittsburgh EDC Pulse Wave Analysis study population 
 
 
 
 
 
Table 9. Multivariate logistic regression model for high coronary artery calcification score (≥100) in The 
Pittsburgh EDC Pulse Wave Analysis study population 
 OR 95%CI p 
Subendocardial Viability Ratio 0.57 0.31-1.07 .08 
Heart Rate 0.73 0.39-1.38 .34 
Age 2.29 1.38-3.81 .001 
Prevalent Hard CAD 7.03 1.65-29.9 .008 
Excludes those reporting nitrate use (n=4). Odds ratios are per standardized unit.  
Variables available to the model: subendocardial viability ratio, age, brachial systolic blood 
pressure, bracial diastolic blood pressure, waist-to-hip ratio, HDL-c, NonHDL-c, sex, HbA1c, 
anti-lipidemic agent use, PWD use (use of at least one: ACE inhibitor, angiotensin II receptor 
blocker, calcium channel blocker, beta-blocker), smoking history, albumin excretion rate.  
Model adjusted for potential confounder: heart rate 
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Table 10. Cross-sectional characteristics of The Pittsburgh EDC pulse wave analysis study population by 
ankle-brachial index category 
 ABI<0.9 0.9<ABI<=1.3 ABI>1.3 
n (%) 16 (11.1) 100 (69.4) 28 (19.4) 
Augmentation Index (%) 27.3±12.0 23.1±10.7 20.4±11.1 
Augmentation Pressure (mmHg) 12.3±7.84 8.77±5.83 8.11±7.64* 
Subendocardial Viability Ratio (%) 126.2±26.1 143.8±32.1 145.5±28.1* 
Heart Rate (bpm) 75.8±12.6 76.9±12.9 80.9±13.8 
Age (years) 49.7±7.61 43.5±7.41  46.0±6.00** 
Diabetes Duration (years) 41.0±6.07 35.2±6.71 37.9±5.88** 
Systolic Blood Pressure (mmHg) 117.6±17.2 114.3±16.8 118.8±15.6 
Diastolic Blood Pressure (mmHg) 60.1±8.59 66.8±9.47 69.3±6.86*** 
Non-HDL-c (mg/dL) 110.2±31.8 115.7±31.9 109.6±36.5 
HDL-c (mg/dL) 57.6±18.8 59.5±16.5 58.7±16.5 
HbA1c (%) 6.99±1.27 7.41±1.33 7.83±1.52 
Waist-to-Hip Ratio 0.89±0.11 0.86±0.09 0.89±0.09* 
Body Mass Index (kg/m2) 29.4±6.48 27.2±4.83 27.2±4.18 
Serum Creatinine (mg/dL) 1.39±1.31 1.04±0.35 1.03±0.24 
White Blood Cell Count (x10-9/L) 7.52±2.80 6.26±1.82 6.43±1.97 
PWD Use  (% (n)) 81.3 (13) 58.0 (58) 67.9 (19) 
ACEI/ARB  (% (n)) 68.8 (11) 52.5 (99) 19.6 (28) 
Beta blocker  (% (n)) 12.5 (2) 10.1 (10) 14.3 (4) 
Calcium Channel Blocker (% (n)) 25.0 (4) 12.1 (12) 7.1 (2) 
Nitrates  (% (n)) 12.5 (2) 2.0 (2) 3.6 (1) 
Abbreviations:“Pulse Wave Drug” (PWD): Use of at least one of the other medications listed below PWD use. 
Angiotensin Converting Enzyme Inhibitor, ACEI; Angiotensin II Receptor Blocker (ARB) 
*p<.10, ** p<.05, ** p<.01, ****<.001. 
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 Table 11. Multivariate models for low ABI (<0.9), excluding those with high ABI (>1.3) in The Pittsburgh 
EDC Pulse Wave Analysis in Type 1 diabetes study population 
Table 11a: Augmentation Pressure and Low ABIa 
Variable OR 95%CI P 
Augmentation Pressure 1.27 0.67-2.42 .47 
Heart Rate  0.91 0.48-1.73 .78 
Height 0.80 0.44-1.45 .46 
Age 2.38 1.24-4.57 .009 
Body Mass Index 1.61 1.24-4.57 .10 
Table 11b: Subendocardial Viability Ratio and Low ABIb 
 OR 95%CI P 
Subendocardial Viability Ratio 0.36 0.15-0.86 .02 
Heart Rate 0.43 0.19-1.09 .08 
Prevalent CAD 6.04 1.73-21.1 .005 
Body Mass Index 1.61 0.94-2.75 .08 
Odds Ratios are per standardized unit.  
aAugmentation pressure along with heart rate and height, were forced into a base model.  
bheart rate entered followed by forward regression allowing for SEVR other variables listed 
here. Variables available to both models forward regression: age, systolic blood pressure, 
diastolic blood pressure, body mass index, sex, history of smoking, HDL-c, Non-HDL-c, 
HbA1c, albumin excretion rate, waist-to-hip ratio, anti-lipidemic agent use. PWD use (use of a 
“pulse wave drug”, 1 or more of the following: ACE Inhibitor, Angiotensin II Receptor 
Blocker, Calcium Channel Blocker, Beta Blocker, Nitrate).  
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 5.1 ABSTRACT 
BACKGROUND: Diabetic nephropathy, a major type 1 diabetes (T1D) complication is a potent 
risk factor for cardiovascular disease (CVD). Known risk factors do not entirely account for its 
development and progression, and its relationship with CVD is not wholly understood. 
Microalbuminuria, an early marker of renal damage, is a major predictor of future CV mortality 
and morbidity in T1D.  Therefore, we examined the relationship between arterial stiffness 
indices, which are shown to predict CVD, and microalbuminuria in T1D and assessed their 
association with renal function.  
METHODS: Pulse wave analysis was measured using the Sphygmocor Px device on 144 
participants in The Pittsburgh EDC Study of childhood onset T1D.  Arterial stiffness indices 
augmentation index (AIx) and augmentation pressure (AP) as well as subendocardial viability 
ratio (SEVR, an estimate of myocardial perfusion) were each analyzed, cross-sectionally, in 
relation to prevalent microalbuminuria (and degree of albuminuria) and renal function. Albumin 
excretion rates (AER) were calculated from timed samples; microalbuminuria was defined as 
AER 20-199 μg/min. Renal function was assessed by two techniques, calculated estimated 
glomerular filtration rate (eGFR) and by serum Cystatin C.  
RESULTS: AP and SEVR were each univariately associated with AER, eGFR and Cystatin C. 
SEVR was independently related to the presence of microalbuminuria and degree of albuminuria 
within normo- and micro-albuminuric participants. Reduced SEVR was independently associated 
with low eGFR (<60 ml/min/1.73m2) and high Cystatin C (≥1.0 mg/l). 
CONCLUSION: Decreased SEVR and increased AP are each related to both early renal damage 
and poor renal function in T1D. SEVR is a better predictor of AER than traditional brachial 
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blood pressure measures in those without clinical proteinuria indicating a potential use for early 
detection, intervention and risk stratification in T1D.  
5.2 INTRODUCTION 
Diabetic nephropathy (DN) is a major complication of type 1 diabetes (T1D)[35] and is 
the most common cause of end-stage renal disease (ESRD) [229, 230]. Known risk factors for 
DN in T1D include poor glycemic control, age and diabetes duration, dyslipidemia [231] and 
elevated blood pressure (brachial systolic and mean arterial pressure [50, 52]). However, these 
factors do not entirely explain the risk of nephropathy development on its progression. DN is 
linked to other complications of T1D such as retinopathy [232, 233] and cardiovascular disease 
[66, 76, 77] in T1D populations while in the general population reduced renal function has been 
associated with greater cardiovascular mortality [234-236], increased left-ventricular mass in 
men [237], and subclinical atherosclerosis[238-240]. Albuminuria (measure of renal damage) is 
also associated with increased risk of clinical cardiovascular disease (CVD) and mortality in a 
variety of populations [234, 241-243]. Despite extensive studies, the underlying mechanism 
relating renal function and/or renal damage to cardiovascular complications are not completely 
understood.  
Augmentation Index (AIx), a index of arterial stiffness, has been linked to progression to 
ESRD in patients with chronic kidney disease [244] and was recently shown to be associated 
with GFR in hypertensive patients [245]. Pulse wave velocity (PWV), a measure of arterial 
stiffness is also shown to be significantly and independently correlated with eGFR (estimated 
with the Modification of Diet in Renal Disease (MDRD) equation) [246, 247]. PWV is also 
 shown to increase in a stepwise manner with advancing stage of CKD (stages 1-5) [248]. 
Measures of arterial stiffness are also associated with left ventricular diastolic function [195], 
cardiovascular events, mortality [113, 249-251] and risk [195].  Pulse wave analysis (PWA) 
utilizing applanation tonometry measures variables associated with the forward propagation and 
reflection of the pulse wave providing indices of arterial stiffness.  The pressure wave created by 
left ventricular contraction propagates forward until meeting sites of resistance which reflect the 
wave backward. Stiffer artery walls result in earlier wave reflection [168, 171]. When the 
reflected wave returns during systole rather than diastole, as occurs when there is increased 
stiffness, systolic pressure is increased or “augmented”. Augmentation pressure (AP, in mmHg) 
is a measure of how much the early reflected wave contributes to central systolic pressure. AIx 
(in %), represents the level of augmentation measured and is expressed as a percentage of the 
pulse pressure (PP= systolic – diastolic blood pressure; AIx=(AP/PP)x100). Subendocardial 
viability ratio (SEVR), the ratio of the diastolic area under the curve (AUC) of an arterial pulse 
wave, divided by the systolic –AUC [190, 191] is an estimate of myocardial perfusion.  The 
association between PWA measures and measures of renal function and/or renal damage, have 
yet to be explored in a T1D population. Therefore, the aim of this study is to examine the 
relationship between PWA measures, AIx, AP and SEVR and measures of renal function (eGFR 
and Cystatin C) and renal damage (albumin excretion rate (AER)) in a population with childhood 
onset T1D.  
78 
 5.3 METHODS 
A cross-sectional study at the 18-year follow-up of participants in The Pittsburgh 
Epidemiology of Complications (EDC) study with childhood-onset (age <17 years) T1D was 
completed. Individuals were diagnosed with T1D, or seen within 1 year of diagnosis, at 
Children’s Hospital of Pittsburgh between 1950 and 1980 and were on insulin therapy at initial 
discharge [27, 176]. Initial evaluation in the EDC Study occurred between 1986 and 1988 and 
biennial reexamination followed for 10 years, then followed up by survey and finally a full 
reexamination at 18 years, during which pulse wave analysis via applanation tonometry was 
performed. The study protocol was approved by The University of Pittsburgh Institutional 
Review Board.  
Questionnaires concerning demographic, health care, self-care, and medical history were 
sent to participants prior to clinic visit. Self-reported smoking history (at least 100 cigarettes in 
lifetime), current smoker status and medication use were obtained. All medications were coded 
according to The World Health Organization’s Anatomical, Therapeutical, Chemical 
Classification/Defined Daily Doses (ATC/DDD) codes. Medications with potential effects on 
pulse wave analysis measures (angiotensinogen converting enzyme inhibitors (ACEI), 
angiotensin II receptor blockers (ARB), calcium channel blockers (CCB), beta blockers (BB), 
and nitrates) [165] were of particular interest and use of 1 or more of these medications was 
categorized as pulse wave drug (PWD) use.  
During clinic visits, brachial systolic and diastolic blood pressures (SBP and DBP) were 
measured using a random zero sphygmomanometer, according to the Hypertension Detection 
and Follow-Up Program protocol, after a 5-minute rest [180]. Hypertension was defined as a 
blood pressure ≥130/80 mmHg or the use of antihypertensive medications for the purpose of 
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 lowering blood pressure. Height (in cm) and weight (in kg) were measured and body mass index 
(BMI) calculated and expressed as kg/m2. Waist and hip circumferences were measured twice 
and if not within 0.5 cm, then a 3rd time. Means of waist and means of hip measurements were 
used to calculate waist-to-hip ratio (WHR).  
Total cholesterol was measured enzymatically [181, 182]. High-density lipoprotein 
cholesterol (HDL-c) levels were determined by a precipitation technique (heparin and 
manganese chloride) with modification [183] of Lipid Research Clinics method [184]. Non-
HDL-c levels were calculated by subtracting HDL-c from total cholesterol.  Blood samples were 
analyzed for hemoglobin A1c (HbA1c) using the DCA 2000 analyzer (Bayer Diagnostics, 
Tarrytown, NY).  Estimated glucose disposal rate (eGDR, a measure of insulin sensitivity) was 
calculated using a regression equation derived from hyperinsulinemic-euglycemic clamp studies 
of 24 subjects chosen to represent the full spectrum of insulin resistance, represented by using 
insulin resistance risk factors: eGDR = 24.4 - 12.97(WHR) - 3.39(HTN) -0.60(HbA1c) [36]. 
Both urinary and serum albumin were measured by immunonephelometry [186, 187]. 
Serum creatinine was assayed using an Ectachem 400 Analyzer (Eastman Kodak Co, Rochester, 
NY). Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet 
in Renal Disease (MDRD) equation [252]: 175 x serum creatinine (mg/dl)-1.154 x age-0.203 x 
[0.742 if female] x [1.21 if black]. Renal function categories were created based on MDRD 
eGFR calculations as follow: No renal insufficiency (eGFR≥90ml/min/1.73m2), mild renal 
insufficiency (eGFR 60-89), moderate insufficiency (30-59), severe insufficiency (15-29) and 
ESRD (<15). Cystatin C is measured turbidimetrically on an Olympus AU 640 using reagents 
purchased from DakoCytomation N. America, Inc. (Carpiteria, CA).  In brief, samples are 
incubated at room temperature for 5 minutes with rabbit anti-cystatin C (antibodies coupled to 
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 polystyrene particles).  The increase in absorption at 540 nm is measured.  Blanks, controls and 
standards (0.4 to 8.0 mg/L) are run simultaneously with all samples.  The intra- and inter-assay 
coefficients of variation are 1.7% and 2.2%, respectively. Cystatin C was categorized as high if 
>1.0 and normal if <1.0 mg/l. Albumin excretion rates (AER) were calculated using urinary 
albumin levels from at least 2 validated timed sample collections. Degree of albuminuria was 
categorized as normo- (AER<20 µg/min), micro- (20-200 µg/min) or macro-albuminuria (> 200 
µg/min). Those reporting a history of renal transplant or dialysis were considered to have a 
history of renal failure and were excluded from this analysis.  
Of those EDC study participants examined at baseline (n=658), 22.7% (n=150) had died 
by the 18-year follow-up (November 2004 – November 2006), 78 had moved out of area, 101 
declined exam, 19 were lost to follow-up leaving 318 eligible for 18 year exam, 309 for which 
data was available for this analysis. Pulse waveform analysis (PWA) testing began part way 
through the 18-year examination period (January 2006), after which 189 subjects were seen and 
144 (76%) had PWA. The PWA population thus 144 men and women in attendance at the 18-
year follow-up clinic visit after January 1 2006. Aortic augmentation index (AIx), aortic 
augmentation pressure (AP) and subendocardial viability ratio (SEVR) were derived using 
waveforms measured at the radial artery using the SphygmoCor Vx version 7.01 (AtCor 
Medical, Sydney, Australia). In brief, a high-fidelity micromanometer with a frequency response 
of >2 kHz (Millar Instruments, Houston, TX) was placed on the right radial artery, and gentle 
pressure was applied until a consistent waveform was produced. After at least 20 sequential 
waveforms had been acquired, measurement was stopped. Central pressure values were 
estimated from radial measurements using the software’s mathematical transfer function [159, 
189]; the accuracy and reliability of which have been validated [163, 172]. The pressure wave 
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 created by left ventricular contraction propagates forward until meeting sites of resistance which 
reflect the wave backward. Stiffer artery walls result in earlier wave reflection [168, 171]. When 
the reflected wave returns during systole rather than diastole, systolic pressure is increased or 
“augmented”.  Augmentation pressure (AP) is a measure of how much the early reflected wave 
contributes to central systolic pressure. Augmentation index (AIx) represents the level of 
augmentation measured and is expressed as a percentage of the pulse pressure (AIx = AP/PP). 
Heart rate is inversely associated with AIx and AP [121]. Subendocardial viability ratio (SEVR), 
the ratio of the diastolic area under the curve (AUC) of an arterial pulse wave to the systolic-
AUC [190, 191] is a ratio of myocardial perfusion (as coronary artery perfusion takes place 
primarily during diastole) to myocardial contraction, and is a tonometric, non-invasive measure 
of myocardial perfusion relative to cardiac workload. The SphygmoCor device provides a quality 
index (QI) which represents reproducibility of the waveform. If PWA produced results with a 
QI<80 the measure was repeated. Measures with a QI≥80 were included in this study. 
Distributional characteristics and normality of variables were assessed. AP, AER, 
cystatin c were all non-parametric. Student’s t-test (for paramentric) and the Mann-Whitney U 
test (for non-parametric) were used to compare continuous variables between two groups. One-
way ANOVA (parametric) or Kruskal-Wallis tests (non-parametrtic) were use for comparisons 
among >2 groups and the χ2 test was used for categorical variables. Pearson’s and Spearman’s  
correlations were used as appropriate. Linear and logisitic regression were performed in a 
stepwise manner for continuous and binary outcomes, respectively. A significance level of 0.10 
was used as the cut-off for entry into models (due to limited sample size).  All continuous 
variables were standardized by subtracting the mean and dividing the by their standard deviation 
of the study population.  Models were adjusted for potential confounders of PWA measures 
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 (height and heart rate for AIx and AP and heart rate only for SEVR).  Age and sex were not 
available to multivariate models for MDRD eGFR as both of these factors are involved in its 
calculation. Analyses were completed using SPSS v15 for Windows.  
5.4 RESULTS 
Of the 144 EDC participants with PWA measures, 11 were excluded from present 
analyses due to history of renal failure (transplant or dialysis). Mean age±SD and T1D duration 
for the remaining 133 were 44.3±7.37 and 36.1±6.65. Of the 133, 130 had available AER 
measurements, variables were available for calculation of MDRD eGFR for 129, and 118 had 
Cystatin C measures.  
5.4.1 Pulse Wave Analysis Measures and Microalbuminuria 
Ninety-one of the 130 with AER measures were normoalbuminuric, 25 had 
microalbuminuria (MA) and 14 had macro. Systolic and diastolic blood pressures increased 
significantly with increasing albuminuria category as did HbA1c, WHR and, as expected so did  
serum creatinine, cystatin c and eGFR (Table 12). eGDR decreased with increasing albuminuria 
category. BMI, although showed a borderline significant, positive linear trend with albuminuria 
category, did not significantly differ among the groups. 
AIx, did not significantly differ by albuminuria category, and did not show a significant 
linear trend (Table 12 and Figure 4). AP increased with increasing albuminuria category (p=.07) 
with a significant, positive, linear trend (p=.01) (Table 12 and Figure 5). SEVR differed 
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 significantly by albuminuria category (p=.002) and showed a significant, negative, linear trend 
(p=.002) (Table 12 and Figure 6). In unadjusted, univariate correlations, only SEVR was 
correlated, negatively, with AER (r= -.35; p<.001). After adjustment for heart rate (and height 
for AP and AIx), SEVR remained significantly correlated with LnAER (r= -.22; p=.01) and 
LnAP was positively correlated (r=.28; p=.001) (Table 13).  
To determine if PWA measures were associated with early renal damage, multivariate 
logistic regression was performed excluding those with macroalbuminuria. AP did not remain 
significantly associated with presence of MA in multivariate models. It also was not significantly 
associated with LnAER in linear regression analysis.  However, each standardized unit decrease 
in SEVR was associated, multivariately, with a 65% increased risk for MA (Table 14). In fact, 
SEVR preferentially entered multivariate models for MA, over brachial SBP and DBP measures. 
Lower eGDR was also associated with presence of MA, multivariately (OR=0.35; 95%CI: 0.17-
0.73; p=.005). Adjustment for PWD use or just ACEI/ARB use, did not significantly alter 
models and neither was significantly associated with MA. In linear regression for LnAER, 
among those within the normo- and micro-albuminuric range, SEVR was again significant and 
entered the model over SBP and DBP. Lower HDL-c was also associated with increased LnAER 
in this model (Table 15). Factors associated with increased LnAER in the total population (with 
macroalbuminuric participants included) were increased SBP and Non-HDL-c (data not shown).  
5.4.2 Pulse Wave Analysis Measures and Renal Function 
Participant characteristics by renal function categories, both eGFR and Cystatin C, are described 
in Table 16 and Figures 4 through 6 illustrate means (standard error) of AIx, AP and SEVR, 
respectively by renal function categories.  
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 AIx, AP and SEVR were all significantly correlated with MDRD eGFR in univariate and 
in heart rate and height adjusted correlations. (Table 13). Increased AIx (p=.09), AP (p=.03), age, 
SBP, WHR, AER, serum creatinine and Cystatin C accompanied decreased eGFR category 
(Table 16).  SEVR, although showing a significant borderline linear trend (p=.07), declining with 
decrease in eGFR category, did not differ significantly between the groups (p=.17).  
Augmentation pressure showed, negative, linear trend (p=.005), as did AIx (p=.02), increasing 
with decreasing eGFR category (Table 16, Figure 5 and 4, respectively). A comparison between 
those low eGFR (<60) and those with normal to mildly impaired renal function (≥60) showed a 
significant difference in AIx (p=.02), AP (p=.006), but not SEVR (p=.13) between the two 
groups. However, multivariately, lower SEVR was associated with a 56% increased risk for low 
eGFR (<60), was selected over brachial SBP and DBP measures, and remained significantly 
associated with low eGFR when adjusted for heart rate and ACEI/ARB medication use. No other 
factors were significantly associated with eGFR in this model (Table 16). Adjustment for PWD 
use instead of ACEI/ARB use did not significantly alter the model. Neither AIx nor AP were 
significant in multivariate models for low eGFR. Linear regression for eGFR in the total 
population showed similar results for AIx, AP and SEVR. However, SBP diminished the 
statistical significance of the SEVR-eGFR relationship in that model.  
 
Cystatin C 
Cystatin C was significantly correlated with AP and SEVR, but not with AIx, in 
univariate and heart rate and height adjusted correlations (Table 13). Those with high Cystatin C 
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 (≥1.0) did however have significantly higher AIx (28.1±12.1 vs. 21.3±10.6; p<.05, Figure 4) and 
AP (13.6±9.98 vs. 7.71±4.88; p<.01, Figure 5), compared to those with normal Cystatin C levels 
(<1.0). SEVR, although about 10 units lower in those with higher Cystatin C, was not 
significantly different between the groups (Figure 6).  Other factors univariate associated, with 
high Cystatin C were older age (but not longer diabetes duration), lower eGDR, higher SBP (but 
not DBP), and expectedly, higher AER , serum creatinine and eGFR (all p<.001).  Results of 
logistic regression for Cystatin C were similar to those seen for low eGFR.  AP, although 
significant when heart rate and height adjusted only, did not remain significant multivariately. In 
multivariate models for high Cystatin C with SEVR available; for each standardized unit 
decrease in SEVR there was a 69% increased risk for high Cystatin C (Table 18). A model with 
brachial SBP and DBP was also run in which both SEVR and SBP were significantly associated 
with high Cystatin C. However, the model with hypertension status was more significant that 
with SBP. Adjustment for PWD use instead of ACEI/ARB use did not substantially change the 
model. Neither age, nor sex, entered models for Cystatin C. 
5.5 DISCUSSION 
The prominent findings of the present study are that pulse wave analysis measures, augmentation 
pressure (an index of arterial stiffness) and subendocardial viability ratio (an estimate of 
myocardial perfusion) are associated with both renal damage, even at the microalbuminuric 
level, and with poor renal function, in our Type 1 diabetes population.  The relationship SEVR 
had with both renal function and renal damage remained present in multivariate models, and 
SEVR was preferred over brachial SBP and DBP as a predictor of albumin excretion rate, 
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 microalbuminuria in those with no to mild renal damage. It was also preferred over SBP and 
DBP in the multivariate model for high Cystatin C and that for low eGFR.  
 Univariately, AIx was not associated with AER (continuously or categorically), was only 
borderline significant in its associated with eGFR (continuously and categorically) and was 
associated with high Cystatin C compared to normal but not with Cystatin C continuously. In the 
Hoorn Study, there were significant increases in aortic AIx with increasing albuminuric quartile 
(measured using urinary albumin-to-creatinine ratio (ACR) in a general population[253]. 
However, after adjusting for age, sex, glucose tolerance status and mean arterial pressure, AIx 
was no longer significantly associated with ACR. This study also found no significant 
relationship between AIx and eGFR (also MDRD calculated), which is consistent with the 
findings of the present study.  It is important to note, however that The Hoorn Study did find an 
association between other measures of vascular stiffness and both ACR and eGFR. In the present 
study, higher augmentation pressure was associated with higher AER and higher albuminuric 
category and with eGFR and Cystatin C. The difference in the associations of AIx and AP with 
renal damage and renal function may be due to the notion that AIx has limitations in its use as an 
arterial stiffness index due to its calculation: AP ÷ PP. Simultaneous rises in both AP and PP can 
result in a stable AIx, thereby reducing its usefulness as a surrogate for change in central 
pressure waveforms [254]. This limitation is especially apparent in older populations, for which 
AP may be a more suitable measure of arterial stiffness [202], and may be pronounced in T1D 
populations due to higher pulse pressures and accelerated vascular aging [153, 254].  
To date, no studies have examined the relationship between SEVR and renal function or 
renal damage. Our finding suggest that, estimated myocardial perfusion is reduced in those with 
greater damage and reduced function. This is even true when comparing microalbumuric T1D 
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 participants to those within the normal range. This finding is consistent with the fact that 
albuminuria, even at the micro level, is associated with CAD in T1D and other populations [54, 
67, 76, 255, 256]. 
In our renal function analyses, we looked at both eGFR and Cystatin C due to the current 
use of eGFR in clinical practice and due to recent findings that Cystatin C may be superior to 
serum creatinine in assessing GFR, especially in T1D populations[257-259].  AP was associated 
with eGFR and Cystatin C, but the addition of SBP to the multivariate models eliminated the 
statistical significance of the association. This is not surprising since AP represents the increase 
of central systolic blood pressure due to early return of the reflected pulse wave which would be 
represented in an increase in brachial SBP. In the absence of brachial BP measures, AP remains 
significantly associated with eGFR and Cystatin C.  Yoshida et al. found an association, albeit 
weak, between increased brachial-ankle PWV, another measure of arterial stiffness, and eGFR in 
those with normal to mild (MDRD calculated eGFR ≥60 but less than 90 ml/min/1.73 m2) renal 
function impairment[260]. Wang et al found a stepwise increase in PWV with decreasing CKD 
category[248]. Although, we also found an association between arterial stiffness as measured 
with AP, and renal function, the only significant association was found when comparing those 
with normal and mild impairment to those with moderate to severe impairment. In other 
regression models, linear in the entire or portions of the population (no to mild impairment, 
moderate to severe) and logistic for mild impairment compared to normal function, neither AP 
nor SEVR was associated with the eGFR outcomes.  
Chade et al.  showed that low eGFR (MDRD calculated <60 ml/min/1.73 m2) was 
univariately associated with coronary microvascular dysfunction (defined as coronary flow 
reserve (CFR) <2.5, evaluated using intracoronary adenosine)[261]. This is consistent with our 
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 finding that SEVR is associated with eGFR. However, in Chade et al’s multivariate analysis, the 
association did not remain significant. The attenuation of the association between renal function 
and reduced CFR was adjustment for age and gender.  In our own multivariate analysis detailed 
in Table 17, we did not make age or sex available to the eGFR models. Since age and sex are 
used in the calculation of MDRD eGFR, adjustment for these factors is redundant. When we ran 
models allowing for these two variables, they did enter the models with over inflated odds ratios. 
By not allowing age and sex to distort the analysis, we find that SEVR is associated with renal 
function as measured by eGFR, which is confirmed by the analysis for Cystatin C which did 
allow for both age and sex and SEVR was significantly related to high Cystatin C.  
In summary, higher augmentation pressure and lower subendocardial viability ratio are 
associated with both renal damage and renal function in T1D. Of great importance is the positive 
relationship between SEVR in those with no or mild renal damage, during which SEVR was a 
better predictor of AER than SBP. These findings underscore the importance of measuring and 
understanding more aspects of the entire pulse wave rather than only brachial SBP and DBP. 
Pulse wave analysis can be quickly and easily measured in a clinical setting and can provide 
additional information for renal complication risk stratification than SBP and DBP alone.  Early 
medication intervention to reduce arterial stiffness in those with higher risk such as with ACEI’s 
or ARB’s may prevent renal complications in T1D. Additional, prospective research should be 
completed to confirm these cross-sectional findings.  
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Table 12. Characteristics of The Pittsburgh EDC Pulse Wave Analysis population by Albuminuria Category 
 
 
Normo 
(n=91) 
Micro 
(n=25) 
Macro 
(n=14) 
Total 
(n=130) 
Augmentation Index % 22.1±11.0 21.1±10.1 26.1±12.1 22.9±11.0 
Augmentation Pressure (mmHg)b** 7.54±4.62 8.84±7.13 13.7±10.4 8.90±6.5 
Subendocardial Viability Ratio (%)b*** 149.3±26.5 126.7±30.3 131.6±35.6 142.0±31.3
Age (years) 43.3±6.57 46.8±8.69 44.2±7.41 44.5±7.30 
Diabetes Duration (years) 35.2±6.09 39.1±7.38 35.1±6.77 36.2±6.71 
Sex (% male) 46.2 60.0 57.1 48.9 
HbA1c (%)c*** 7.33±1.15 8.00±1.70 8.28±1.30 7.56±1.33 
eGDR (mg/kg/min)d**** 8.33±1.97 6.82±2.27 5.56±2.21 7.74±2.26 
Systolic Blood Pressure (mmHg)d**** 109.3±11.5 115.7±13.1 139.5±15.5 115.1±15.9
Diastolic Blood Pressure (mmHg) c**** 65.4±8.23 63.3±9.12 75.6±11.7 66.4±9.22 
Heart Rate (bpm) 76.7±13.0 82.6±12.4 79.9±14.0 77.8±13.0 
Non-HDL-c (mg/dL) 111.1±27.3 107.0±34.0 144.9±52.8 114.0±33.0
HDL-c (mg/dL) 60.3±16.7 55.5±15.8 57.115.9 59.2±16.5 
Body Mass Index (kg/m2)a 26.7±4.34 27.3±4.89 28.9±3.99 27.1±4.50 
Waist-to-Hip Ratiob*** 0.85±0.09 0.91±0.09 0.90±0.7 0.87±0.09 
Serum Creatinine(mg/dL)d**** 0.93±0.17 1.12±0.42 1.32±0.39 1.08±0.54 
eGFR (ml/min/1.73 m2) d**** 78.4±15.1 69.7±19.9 56.7±18.0 74.5±17.7 
Cystatin Cd**** 0.80±0.12 0.98±0.34 1.24±0.50 0.95±0.43 
Abbreviations: estimated glucose disposal rate, eGDR; estimated glomerular filtration rate, 
eGFR. *<.10, **<.05, ***<.01, ****<.001.   
asignificant linear trend <.10  
bsignificant linear trend <.05  
csignificant linear trend <.01  
dsignificant linear trend <.001 
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Figure 4. Augmentation Index (mean and standard error) by albuminuria and renal function categories in 
The Pittsburgh EDC Pulse Wave Analysis Population 
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Figure 5. Augmentation Pressure (mean and standard error) by albuminuria and renal function categories in 
The Pittsburgh EDC Pulse Wave Analysis study population 
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Figure 6. Subendocardial Viability Ratio (mean and standard error) by albuminuria and renal function 
categories in The Pittsburgh EDC Pulse Wave Analysis study population 
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 Table 13.  Bivariate correlations and heart rate adjusted partial correaltions between Augmentation 
Index, Augmentation Pressure, Subendocardial Viability Ratio and Albumin Excretion rate, Estimated 
Glomerular Filtration Rate and Cystatin C in The Pittsburgh EDC study 
 Albumin Excretion Rate 
(μg/min) 
MDRD eGFR 
(ml/min/1.73 m2) 
Cystatin C 
(mg/l) 
AIx -.074 -.210** .108 
AP .050 -.252*** .209** 
SEVR -.354**** .212** -.186** 
Heart Rate Adjusted Correlations 
 LnAERb MDRD eGFR Cystatin C 
AIx .138 -.175** .170 
LnAPa,b .281*** -.249*** .273*** 
SEVRa -.223** .257*** .283*** 
Abbreviations: Modification of Diet in Renal Disease, MDRD; estimated glomerular filtration 
rate, eGFR; Augmentation Index, AIx; Augmentation Pressure, AP, Subendocardial Viability 
Ratio, SEVR. 
*<.10, **<.05, ***<.01, ****<.001.  
aalso height adjusted, b Due to use of Pearson’s partial correlations, AER was natural 
logarithmically transformed because non-parametric 
 
 
 
Table 14. Logistic regression model for microalbuminuria in The Pittsburgh EDC Pulse Wave Analysis study 
population 
Variable OR 95%CI p 
Subendocardial Viability Ratio 0.35 0.17-0.73 .005 
Estimated Glucose Disposal Rate 0.52 0.30-0.89 .017 
Heart Rate  0.72 0.38-1.38 .32 
Odds Ratios are per standardized unit.  
Variables available to the model: age, subendocardial viability ratio systolic blood pressure, 
diastolic blood pressure, waist-to-hip ratio, estimated glucose disposal rate, HDL-cholesterol, 
Non-HDL-cholesterol, Smoking history, ACE inhibitor/Angiotensin II receptor blocker use, 
heart rate, body mass index, anti-lipidemic agent use 
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Table 15. Linear regression model for albumin excretion rate in those within the normal and micro-
albuminuric range. 
 β standard error p 
Subendocardial Viability Ratio -11.3 3.71 .003 
HDL-c -6.56 2.64 .015 
Heart Rate -5.76 3.68 .13 
All variables are standardized to the population 
Variables available to the model: age, subendocardial viability ratio systolic blood pressure, 
diastolic blood pressure, waist-to-hip ratio, estimated glucose disposal rate, HDL-cholesterol, 
Non-HDL-cholesterol, Smoking history, ACE inhibitor/Angiotensin II receptor blocker use, 
heart rate, body mass index, anti-lipidemic agent use
 Table 16. Cross-sectional characteristics by renal function categories in The Pittsburgh EDC Pulse Wave Analysis Study Population 
 Estimated Glomerular Filtration Rate Cystatin c 
 >90 
(n=29) 
60-89 
(n=75) 
30-59 
(n=22) 
15-30 
(n=3) 
 <1.0 
(n=98) 
≥1.0 
(n=20) 
Augmentation Index 19.9±10.8b* 22.3±10.8 27.2±9.38 27.0±9.85 21.3±10.6** 28.1±12.1 
Augmentation Pressure 7.00±5.11c** 8.24±5.97 11.8±7.71 12.7±5.78 7.71±4.88*** 13.6±9.98 
Subendocardial Viability Ratio 147.2±24.1b 143.1±32.2 138.2±36.4 106.7±19.1 143.9±29.4 133.6±42.1 
Age 40.6±4.37 b**** 44.2±7.83 49.6±5.98 47.7±6.20 43.7±7.12*** 49.2±6.58 
Diabetes Duration 33.9±5.34 c*** 35.2±6.70 40.1±7.02 33.2±6.07 36.0±6.33 37.9±7.20 
Sex (% male) 58.6* 53.3 27.3 33.3 55.1 40.0 
HbA1c 7.71±1.62 7.52±1.27 7.41±0.97 7.53±1.32 7.53±1.28 7.56±1.34 
Estimated Glucose Disposal Rate 7.88±2.36 7.93±2.09 7.54±2.11 5.37±3.08 7.94±2.09** 6.64±2.51 
Systolic Blood Pressure 108.5±13.4c*** 114.4±14.3 118.2±20.7 136.7±9.50 112.4±14.3** 124.3±19.3 
Diastolic Blood Pressure 67.2±7.07 65.7±9.30 65.3±11.0 75.7±16.3 65.6±8.42 66.7±13.9 
Heart Rate 78.0±13.1 79.1±13.7 74.7±10.6 86.7±8,08 79.0±12.9 74.2±13.1 
Non-HDL-c 111.3±28.1 116.3±33.1 109.6±37.44 100.0±51.1 111.5±31.9 119.2±40.8 
HDL-c 59.3±17.2 60.0±16.7 57.5±15.8 47.7±6.43 58.6±16.3 57.2±16.1 
Body Mass Index 26.5±4.46a 26.9±4.39 28.5±4.86 29.3±3.16 26.7±4.26 27.1±4.20 
Waist-to-Hip Ratio 0.86±0.07b*** 0.86±0.09 0.88±0.10 0.94±0.13 0.87±0.09 0.90±0.10 
Albumin Excretion Rate 9.73±12.9d**** 129.4±442.3 195.4±396.9 646.9±734.8 96.7±385.8**** 669.1±1563.1
Serum Creatinine 0.80±0.10d**** 0.97±0.13 1.24±0.25 2.33±0.51 0.94±0.16**** 1.42±0.50 
Cystatin C 0.74±0.08d**** 0.82±0.12 1.09±0.24 1.87±0.25 -- -- 
MDRD eGFR -- -- -- -- 78.9±14.1**** 49.0±14.6 
Comparisons between MDRD eGFR categories: *<.10, **<.05, ***<.01, ****<.001.  
   asignificant linear trend <.10, bsignificant linear trend <.05, csignificant linear trend <.01, dsignificant linear trend <.001
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 Table 17. Multivariate logistic regression model for low estimated glomerular filtration rate (eGFR<60) in 
The Pittsburgh EDC Pulse Wave Analysis Study 
 Odds Ratio 95%CI p 
Subendocardial Viability Ratio 0.44 0.22-0.89 .02 
Heart Rate 0.42 0.20-0.88 .02 
ACEI/ARB Use 3.57 1.18-10.8 .02 
All variables are standardized to the population and odds ratios are expressed as per standardized 
unit.  
Variables available to the model: subendocardial viability ratio, systolic blood pressure, diastolic 
blood pressure, hypertension status (BP>130/80 or use of medication to reduce blood pressure), 
waist-to-hip ratio, estimated glucose disposal rate, HDL-cholesterol, Non-HDL-cholesterol, 
Smoking history, ACE inhibitor/Angiotensin II receptor blocker (ACEI/ARB) use, heart rate, 
body mass index, anti-lipidemic agent use 
 
 
 
 
 
 
 
 
 
Table 18. Multivariate logistic regression model for high Cystatin C (≥1.0 mg/l) in The Pittsburgh EDC Pulse 
Wave Analysis Study 
 Odds Ratio 95%CI p 
Subendocardial Viability Ratio 0.31 0.13-0.73 .007 
Heart Rate 0.20 0.07-0.57 .003 
Hypertension 6.35 1.88-21.5 .003 
ACEI/ARB Use 5.65 1.21-26.4 .03 
All variables are standardized to the population and odds ratios are expressed as per standardized 
unit.  
Variables available to the model: subendocardial viability ratio, hypertension status (BP>130/80 
or use of medication to reduce blood pressure), waist-to-hip ratio, estimated glucose disposal 
rate, HDL-cholesterol, Non-HDL-cholesterol, smoking history, ACE inhibitor/Angiotensin II 
receptor blocker (ACEI/ARB) use, heart rate, body mass index, anti-lipidemic agent use 
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 6.0  FINAL DISCUSSION 
6.1 SUMMARY AND CONCLUSIONS 
This is the first study to assess potential risk factors (gathered 18 years earlier) for abnormal 
pulse waveform measures (i.e. augmentation index (AIx) and augmentation pressure (AP)) and 
decreased subendocardial viability ratio (SEVR). It is also the first to examine the association 
between these measures and prevalent cardiovascular and renal disease in a T1D population.  
These data document important associations of autonomic neuropathy with both arterial stiffness 
(AIx and AP) and estimated myocardial perfusion (SEVR). They also show that the relationships 
between measures of arterial stiffness and cardiovascular disease are complex due to age, 
diabetes duration and the pervasive use of various medications. It also showed that renal function 
and renal damage, even within the normo- and microalbuminuric range, are  associated with a 
reduced SEVR and increased AP. 
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 6.2 GENERAL FINDINGS 
6.2.1 Participant Characteristics 
The aim of this study was to understand the arterial stiffness measure relationships to 
complications and risk factors within a population not previously well examined in this regard, 
those with type 1 diabetes. Therefore, analysis was completed in The Pittsburgh Epidemiology of 
Diabetes Complications Study, a prospective study in a population with childhood onset Type 1 
diabetes that has been followed for approximately 18 years. At the time of pulse wave analysis, 
the population involved in this aspect of the study was comprised of 73 female and 71 male 
participants. Males had higher blood pressures, lower estimated glucose disposal rate (insulin 
sensitivity), lower HDL-c, better renal function (lower eGFR), but more renal damage (higher 
AER), and a greater percentage with coronary artery disease (Table 19).  Compared to the 
remaining EDC population (those without PWA measures who attended the 18 year follow-up 
clinic visit), our PWA population had higher mean heart rate, smaller waist-to-hip ratio and 
lower albumin excretion rate. A greater percentage of those not in the PWA study had CAD 
compared to those included (30.9% versus 23.1), although this difference did not reach statistical 
significance. Due to these differences, our PWA may represent a somewhat healthier portion of 
the overall EDC study population at the 18 year follow-up.  An important factor included in the 
analyses was the reported use of medications potentially affecting PWA measures. ACE 
inhibitors (ACEI), angiotensin receptor blockers (ARB), beta-blockers, calcium channel blockers 
and nitrates may exhibit some effect on arterial stiffness indices [179] and coronary artery 
perfusion[262-264].  Of the 144 PWA participants, 90 (62.5%) were on at least one of the 
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 aforementioned medications, especially use of ACE inhibitors, reported by 55% (n=79). Another 
14.7% (n=21) reported ARB use, 5 of which were also using an ACEI resulting in 56% (n=80) of 
the PWA population taking either an ACEI or ARB. Wide use of ACEI/ARB medications in the 
present study population is not surprising due to their effectiveness in treating hypertension and 
the known protective effect against renal damage [265, 266].  Both ACEI and ARB medications 
are also shown to be effective in reducing arterial stiffness [267].  Both act on the renin-
angiotensin-aldosterone system (RAAS), the system responsible for the regulation of blood 
pressure.  ACEI’s inhibit the conversion of angiotensin I to angiotensin II (AngII). AngII causes 
vasoconstriction, stimulates the release of aldosterone (acts on kidney to increase sodium 
retention and potassium excretion) from the adrenal cortex and stimulates the release of 
vasopressin (aka: anti-diuretic hormone; acts on kidneys to increase water retention).  All of 
these AngII actions work to increase blood pressure therefore it follows that ACE inhibition 
would cause BP reductions.  ARB’s, on the other hand, block the action of AngII thereby 
reducing blood pressure as well. ACEI have been shown to reduce arterial stiffness independent 
of BP reduction[268] as has ARB use [269]; use of ACEI in conjunction with ARB shows 
synergistic and possibly additive effects on systemic arterial stiffness[270] and in coronary artery 
perfusion [263]. Beyond the aforementioned effect of ACEI on blood pressure, in animal models 
treatment with ACEI is shown to cause reduction in size of the medial (muscular) layer of 
arteries due to reversal of smooth muscle hypertrophy [271] and to decrease the collagen (but not 
elastin) density in arteries  [272] both of which contributed to reductions arterial stiffness seen in 
ACEI treatment.  ACEI and ARB are also shown to improve endothelial function by increasing 
the bioavailability of nitric oxide (NO)[273], a potent vasodilator and regulator of vascular tone.  
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 6.2.2 Risk Factors for  Pulse Wave Analysis Measures 
 Previous studies have suggested that indices of arterial stiffness are significantly higher in those 
with T1D and SEVR is significantly lower, compared to non-diabetic controls [9, 10, 169].  
Duprez et al. studied associations between pulse wave analysis measures and traditional 
cardiovascular risk factors in a non-diabetic population (69% male; mean age 50±12 years) with 
low cardiovascular risk (determined via Framingham Risk Score). The study results showed that 
both AIx and AP were significantly and positively associated with age, SBP, pulse pressure and 
Framingham Risk Score (comprised of age, sex, smoking history, BP, total and HDL cholesterol 
levels and blood glucose or history of diabetes) in both men and women. DBP and mean arterial 
pressure (MAP) as well as total and HDL cholesterol levels were also positively associated with 
AIx and AP in women, but not in men. Interestingly, in the male participants of Duprez et al 
study, total cholesterol, LDL-c, and BMI were all significantly and negatively associated with 
AIx and AP. This was the only published study available that has examined potential risk factors 
for PWA measures; it was in healthy, non-diabetic persons of middle age (50±12), was cross-
sectional in nature and looked only at univariate correlations.  In order to understand what factors 
contribute to increased AIx and AP and decreased SEVR in a T1D population, the present 
research examined the relationship between factors at baseline and the follow-up measures.  We 
too found that AIx and AP were univariate associated with Non-HDL-c (but not HDL-c), systolic 
and diastolic BP in cross-sectional analyses (Table 20).  However, in the adjusted model for AIx, 
only ever smoker status, DBP, and estimated glucose disposal rate were significant while only 
ever smoker status and SBP were independently associated with AP. Of greater interest are the 
significant, independent associations found between baseline HDL-c, E/I ratio and ever smoker 
status and both AIx and AP, as well as the positive association between  baseline HbA1 and AP 
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 in our adjusted models. Arterial stiffness indices and SEVR are significantly affected by age 
[104, 274]. They also tend to be higher in women compared to men[275], which is partially, but 
not entirely, due to shorter stature [276] since height is inversely related to timing of pulse wave 
reflection [120]. Pulse wave reflection, specifically, is also dependent on heart rate. Wilkinson et 
al showed that there is an inverse linear relationship between heart rate and AIx/AP. This 
relationship occurs because faster HR decreases the absolute duration of systole shifting the 
occurrence of reflected wave return to diastole, reducing central pressure augmentation [121].  
Due to the potential confounding effects of age, sex, height and heart rate, the final models 
relating other potential risk factors were adjusted for these variables. Resulting models showed 
that the prominent risk for all 3 measures was reduced ECG monitored deep breathing 
expiration-to-inspiration ratio, a measure of heart rate variability. Lower E/I ratios are indicative 
of autonomic neuropathy [277]. Ahlgren et al showed similar results relating E/I to ultrasound 
derived aortic stiffness measures in women with T1D in cross-sectional analyses.  Taskiran et al 
showed that in T1D, the presence of autonomic neuropathy was associated with decreased 
myocardial perfusion reserve as measured using perfusion reserve index assess from MRI during 
induced vasodialation. This finding is in agreement with that from the present study showing AN 
to be associated with SEVR. Autonomic neuropathy involves damage to the nerves that comprise 
those from the brain and spinal cord to organs such as the heart and to blood vessels.  Our 
finding, that a lower E/I ratio was independently predictive of higher AIx and AP and lower 
SEVR measured some 18 years later is particularly important as it suggests that neutrally 
mediated changes in vascular function may underlie the pathophysiology of increased vascular 
stiffness.  However, our findings also show that both having a history of cigarette smoking and 
poor glycemic control (higher HbA1) at baseline were also predictive of AP and SEVR. 
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 Smoking is a known risk factor for cardiovascular disease [278] and has previously been shown 
to be associated with arterial stiffness measures[129, 200, 209, 279, 280]. Rehill et al. suggest 
that the connection between smoking and systemic arterial stiffness is impaired basal arterial 
tone, an index of endothelial dysfunction [280].  Smoking is associated with reduced 
bioavailability of nitric oxide (NO), which is synthesized in the endothelium of arteries and 
causes vasodilatation and contributes to resting arterial tone and smooth muscle cell proliferation 
[281].  The relationship between AP and history of cigarette smoking therefore is biologically 
plausible and consistent with findings in prior research. The relationship between SEVR and 
smoking history is also consistent as AP affects SEVR and according to Guo et al, cigarette 
smoke affects the wall properties of not only peripheral arteries, but also coronary arteries [282]. 
Alterations in the extracellular matrix of the media and adventitia of arteries have also been 
shown to be associated with increased arterial stiffness [283, 284]. These alterations can be due 
to advanced glycosylation end-product (AGE) accumulation on matrix proteins due to poor 
glycemic control [285]. Therefore, our finding that higher baseline HbA1 is associated with 
increased AP may be due to the influence of AGE’s .  Glycemic control has also been shown to 
be associated with incident coronary artery disease events in T1D [71, 256], which is in 
agreement with the association between poorer control at baseline and higher follow-up SEVR in 
the current study.  The present study also showed that lower HDL-c was associated with higher 
AP and AIx. As low HDL-c is a known risk factor for atherosclerosis, it is therefore reasonable 
that indices are arterial stiffness are elevated as atherosclerosis contributes to increased stiffness. 
The results of the present research suggest that risk factors for increased arterial stiffness include 
those affecting functional (AN) as well as structural (oxidative stress due to smoking, AGE 
accumulation due to poor glycemic control, and atherosclerosis due to low HDL-c) aspects of 
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 arteries and that these factors, along with increased peripheral arterial stiffness, also contribute to 
reduced myocardial perfusion.  
6.2.3 Pulse Wave Analysis and Prevalent Cardiovascular Disease (CVD) 
We are not aware of any study to date that has explored the association between pulse wave 
analysis measures and prevalent or incident CVD in T1D. Numerous studies have however 
shown PWA measures to be higher in populations that have greater risk for CVD including those 
with diabetes [9, 169, 286] and those with renal disease [117, 246, 248].  A few studies have 
published on the relationship between these measures and CVD outcomes either incident or 
prevalent. Those that have been done have not been in T1D. Weber et al. completed PWA in 
male patients undergoing coronary angiography for either diagnosis or exclusion of coronary 
artery disease (CAD) finding that higher AIx and AP were univariately (4th vs. 1st quartile) 
associated with presence of CAD. However, multivariate analysis for CAD was completed only 
with the AIx variable showing that it was also multivariately (controlling for age, height, 
hypertension status, HDL-c and ACEI, beta-blocker and statin use) associated with the prevalent 
CAD[211]. Both AP and AIx were also shown to be independent predictors of major adverse 
cardiovascular events and cardiovascular mortality in those with preexisting CAD [251]. The 
findings of the present study show that AIx was not significantly associated with prevalent CAD 
(any, hard or soft) but that increased AP was associated with presence of hard CAD when those 
reporting nitrate use were excluded. For both AIx and AP as well as for SEVR, the addition of 
age diminished the statistical significance of their associations with the CAD outcomes. As 
previously discussed, AP increases with age and SEVR decreases with age. In type 1 diabetes, 
especially in childhood onset T1D, age and diabetes duration are highly correlated. Type 1 
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 diabetes has been shown to be associated with accelerated vascular aging [153] therefore, age, 
essentially representing both age and diabetes duration in those with childhood onset T1D, seems 
to be the prominent factor associated with increased arterial stiffness, reduced coronary artery 
perfusion and CAD, so much so that it is difficult to decipher the relationship in this cross-
sectional analysis. Due to the limited sample size, stratification by shorter and longer duration or 
older and younger age did not shed any light on this issue.  In this T1D population, age may  
better represent vascular age than in non-diabetic populations. Therefore, the addition of age to 
multivariate models and the subsequent reduction in statistical significance of AP and SEVR 
does not deem the relationship between AP and CAD, and that between SEVR and CAD, 
biologically insignificant.  
Another interesting finding in this CAD analysis was the impact of medications. Those 
with soft CAD had significantly lower SEVR than those without, yet those with hard CAD were 
comparable to those without CAD. A potential explanation for this is the more pervasive use of 
medication in those with hard CAD. In fact, the percentage of those with soft CAD on 
ACEI/ARB (40%) was less than in those without CAD (55.5%).  A greater percentage, 61.1%, of 
those with CAD reported use of at least to different PWD medications compared to 20.0% of 
those with soft CAD and 12.7% of those without CAD. This finding suggests that a more 
pervasive use of medications and the use of multiple medications in those with hard CAD are 
effective in reducing arterial stiffness and improving myocardial perfusion. One type medication 
that seemed very influential, at least on AP, was nitrate use even though only 5 participants 
reported use. Those taking nitrate medications had a mean±SD AIx of 20.1±18.1, AP of 
8.80±10.2 and SEVR of 142.2±21.9 compared to 12.1±10.7, 9.04±6.397 and 142.2±31.5 in those 
not on nitrate medication, respectively. These differences did not reach statistical significance of 
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 course, as there were only 5 persons on nitrate medication. However, it is interesting that 
although 4 of them had Hard CAD the means of the arterial stiffness indices were lower than the 
remainder of the population and that these means were also comparable than those for the non-
CAD participants (AIx: 22.4±9.82; AP:8.09±4.67; SEVR: 144.5±32.4).  
The presence of high CAC score was associated with a significant increase in AP 
(10.9±8.25 vs. 7.98±5.03). Coronary artery calcification was also associated AP and with SEVR 
univariately however, the relationship between AP and high CAC score did not remain 
significant multivariate, again due to the addition of age. However, lower SEVR remained 
significantly associated with high CAC once those taking nitrates were excluded from analyses. 
This finding is consistent with that by Hata et al that CAC is a predictor of ischemic heart disease 
[221] and makes biological sense in that the greater the burden of calcification/atherosclerosis in 
coronary arteries the worse the perfusion of the heart.  Finally, both AP and SEVR were 
associated with presence of low ABI. This finding is consistent with the fact that PWA measures 
are of reflected waves which are reflected back to the aorta from the periphery. If follows that the 
presence of vascular disease in the lower extremities would cause earlier timing of the reflected 
wave.  
6.2.4 Pulse Wave Analysis Measures and Renal Damage and Function 
As previously mentioned, autonomic neuropathy was associated with all of the PWA measures 
examined in this study. Interesting, Maguire, et al found that autonomic nerve testing predicted 
the development of microalbuminuria at 12 year follow up in a cohort of adolescents with 
T1D[287]. Our finding that AP and SEVR were related to albuminuria is consistent with those of 
Maguire et al.  Chico et al found that autonomic neuropathy was associated with silent 
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 myocardial ischemia especially in the presence of microalbuminuria[288] which is in agreement 
with the association between AN and SEVR. It also is consistent with the proposed connection 
between all aspects of this study which will be discussed shortly.   
While renal function relates to the ability of the kidneys to filter the blood, renal damage 
is reflected by the excretion of protein (albumin) in urine at concentrations which would not 
normally be excreted. Albuminuria is a widely recognized and potent risk factor for coronary 
artery disease in those with diabetes [54, 67, 255]. It has been shown, that renal damage typically 
precedes renal function loss in The Pittsburgh EDC population[289], though occasionally 
reduced renal function is seen without preceding albuminuria. The strongest association found in 
this renal analysis was the association between SEVR and albuminuria, specifically at the low 
end.  However, SEVR was also related to presence of poor renal function by both methods used 
to estimate renal function, MDRD eGFR and Cystatin C levels. The pathophysiology behind 
albuminuria-cardiovascular disease connection may involve arterial stiffness.  Greater stiffness 
could potentially cause increased rate of blood flow to the kidneys resulting in kidney damage. 
This damage in turn causes an increase in blood pressure which contributes to further increases 
in arterial stiffness. It may follow that earlier and earlier return of reflected waves due to arterial 
stiffness cause a decrease in time in diastole, thereby reducing coronary artery perfusion 
resulting in coronary ischemia and/or infarction.  
 
6.2.5 The Connections 
The proposed relationship between autonomic neuropathy, arterial stiffness indices and 
subendocardial viability ratio, kidney damage and coronary artery are illustrated in Figure 1. 
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 Autonomic neuropathy causes vascular dysfunction reducing the ability to regulate vascular tone. 
This factor causes an increase in arterial stiffness and perhaps increased or more rapid blood 
flow to the kidneys causing kidney damage. Kidney damage results in higher blood pressure 
levels further increasing arterial stiffness. Autonomic neuropathy (AN) is also associated with 
impaired ability to regulate heart rate. Inability to properly regulate HR is most likely why AN 
was associated with lower SEVR, because this inability may result in reduce the time in diastole.  
The notion that arterial stiffness, due to either functional or structural changes in arteries 
caused by autonomic neuropathy and smoking, poor glycemic control or hypertension, causes 
kidney damage which in turn increases arterial stiffness which contributes to even greater 
increases in blood pressure (particularly systolic), may be the explanation as why AP was related 
renal outcomes until the addition of SBP to multivariate models. Greater decreases in SEVR, on 
the other hand, are most likely due to prolonged stiffness that results in isolated systolic 
hypertension and may be why SEVR maintains its statistical significance. 
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Figure 7.  The proposed relationship between autonomic neuropathy, arterial stiffness, renal disease 
and coronary artery disease in Type 1 diabetes.  
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6.3 STRENGTHS 
This study is one of few that has examined pulse wave analysis in a T1D population, the only 
that has looked at its relationship with prevalent cardiovascular disease and one of few that as 
studied these measures in relation to renal function. Subendocardial viability ratio has been one 
measure obtained through pulse wave analysis that is extremely lacking in the research literature. 
This study also examined SEVR and illustrating its importance in cardiovascular and renal 
disease.  Perhaps the greatest strength is the ability to related risk factors measured 18 years 
earlier to current PWA measures. This allows for the evaluation of variables as potential risk 
factors for later increased arterial stiffness and reduced coronary perfusion.   
Finally, another strength of this study was that the majority of the measurements used in 
this research were obtained by one technician for whom intra-observer reproducibility analysis 
showed excellent reproducibility.  
6.4 LIMITATIONS 
This study had a limited sample size of 144 men and women, which did not allow for stratified 
analyses.  The sex-differences in risk factors associated with augmented central pressure or 
SEVR or their relationship with cardiovascular and renal disease could therefore not be 
examined properly. The pervasive use of medications, particularly those that may potentially 
110 
 affect PWA measures, also makes it difficult to be certain what is occurring patho-
physiologically. Again, the limited sample size did not allow for assessment within those not 
using medications as the majority reported use. Additionally, the lack of pulse wave analysis at 
baseline did not allow for adjustment of baseline stiffness or perfusion measures in the analysis 
of potential risk factors. Finally, the cross-sectional nature of the complications analysis does not 
allow for the establishment of a temporal relationship between PWA measures and complications 
and therefore these relationships must be assessed in a prospective study to evaluate true 
causality. The cross-sectional design may also have prevented appropriate assessment of the 
relationship between PWA measures and coronary artery disease in T1D.  
Although the fact that this T1D cohort has been followed for so long is a strength, it is 
also a limitation in that it is essentially a survivor cohort, therefore it excludes those with the 
worse complications of the disease. Also, pulse wave analysis was not carried out on all EDC 
participants who returned for the 18 year visit. Cross-sectional analysis shows that although 
participants were specifically selected, those who ended up in the PWA represent a slightly 
healthier portion of the 18-year EDC population with lower albumin excretion rates and smaller 
waist-to-hip ratios.  
 In renal analysis, our glomerular filtration rate was estimated using the Modification of 
Diet in Renal Disease formula and not measured directly. However, Cystatin C was also 
examined showing similar results. Albumin excretion rates and serum creatinine levels (used to 
calculate eGFR) were not available for all participants in the PWA study population and Cystatin 
C was available for less than either AER or serum creatinine. Insulin sensitivity was estimated 
using the calculated estimated glucose disposal rate rather than measured using euglycemic 
clamp studies. 
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 Finally, also due to the limited sample size, refinement of the relation between both age 
and duration on arterial stiffness was unable to be assessed. Stratification by older and younger 
age or shorter and longer duration may have helped to understand how each affected PWA 
measures and their relationship with complications.  
6.5 FUTURE RESEARCH 
With regard to repeatability and reproducibility, studies should be completed that examine what 
factors are associated with variability of PWA measures within an individual. These studies 
should be of substantial size and in a variety of populations of males and females, within 
different racial/ethnic groups and various disease states (diabetes, hypertension, renal disease, 
etc).  
Future prospective studies with baseline pulse wave analysis are necessary to confirm the 
findings in this research.  Specifically, the assessment of if PWA measures predict 
cardiovascular and renal outcomes is of great importance.  Studies with larger sample sizes are 
needed to compare and contrast the relationship between risk factors and complications with 
PWA measures in males and females.  Previous studies have found arterial stiffness differences 
between males and females [274, 276, 290-293], therefore there may be potential sex-differences 
in their relationship with disease outcomes. There may also be different risk factors for increase 
arterial stiffness or reduced coronary perfusion by sex which should also be addressed in future 
research.   
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 6.6 CLINICAL UTILITY OF PULSE WAVE ANALYSIS 
Pulse wave analysis allows for quick, non-invasive, measurement and monitoring of a variety of 
features of the pulse wave and estimates central pressure changes. Radial tonometry is simple 
and well-tolerated in a clinical setting, more so than are other techniques for measuring arterial 
stiffness (i.e. PWV, ultrasonography). Recently, The Conduit Artery Functional Endpoint Study 
(CAFÉ) study showed that improvement in PWA measures obtained via radial applanation using 
the Sphygmocor, not brachially measured blood pressures, were associated with reduced risk for 
cardiovascular outcomes[2].  Systolic and diastolic blood pressures vary throughout the arterial 
tree, and brachially measured pressures are ineffective in detecting pressures and pressure 
changes in the aorta due to the reflected pulse wave as brachial pressures are less effected by 
reflected waves. Reductions in brachial systolic pressures do not necessarily signify reductions at 
the aorta, essentially where it counts with respect to cardiovascular outcomes.  Carotid-femoral 
pulse wave velocity is currently considered the gold standard due to its direct measurement of 
factors related to arterial stiffness and primarily due to the large amount of epidemiological data 
linking it to cardiovascular  outcomes. However, if a technique is not used clinically, due to 
inconvenient implementation, it cannot aid in risk stratification or early intervention.  There is a 
reason that measurement of brachial blood pressures have been the means by which hypertension 
has been diagnosed and treated for decades even though it has been known for some time that it 
is suboptimal; it is a matter of convenience.  Pulse wave analysis has the potential to be 
implemented clinically because it requires little set-up, is well tolerated by patients as it only 
requires application of a tonometer to the inside of their wrist, and measurement is an easily 
acquired skill require little expertise. Granted, additional studies should be completed, just as 
they have been for PWV, to more fully understand how PWA measures relate to and predict 
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 clinical outcomes. Guidelines for the methodological issues (i.e. manner in which measurements 
should be obtained, what factors should be considered at the time of measurement (known 
factors include height and heart rate, but blood glucose, time since meals or medication may also 
influence measures) as well as clinical implications, should be published.  
6.7  CONCLUSION AND PUBLIC HEALTH SIGNIFICANCE 
In conclusion, autonomic neuropathy, history of smoking and poorer glycemic control, are 
predictive of increased central pressure augmentation an index of arterial stiffness. These factors 
are also independently associated with poorer coronary perfusion in T1D.  Higher central 
pressure augmentation and lower coronary perfusion are associated with lower-extremity arterial 
disease, renal function and renal damage in this population. SEVR is also associated with higher 
coronary artery calcification burden, and is more significantly associated with degree of renal 
damage than systolic blood pressure in those with no or mild albuminuria.  Confirmation of these 
findings in a larger sample with sex stratified analyses may give rise to better risk stratification 
for complications in those with T1D.  Also, the findings of this research suggest that early 
treatment of autonomic neuropathy, better glycemic control, improvement of lipid profiles and 
smoking cessation within those with T1D may result in slower vascular aging and perhaps 
subsequent cardiovascular outcomes in this already high risk group.   Confirmation of the 
findings regarding renal function and damage in T1D may give rise to better assessment of risk 
and the use of renal protective medications sooner. 
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Table 19. Cross-sectional characteristics (and sex comparisons) of The Pittsburgh EDC Pulse Wave 
Analysis study population and the remaining 18-year EDC follow-up population 
 Female 
N=73 
Malea 
N=71 
PWA Study 
Population 
N=144 
Remaining EDC 
Populationb 
N=165 
Female NA NA 50.7 52.1 
Age (years) 43.9±7.12 45.4±7.76 44.7±7.46 45.3±7.58 
Diabetes Duration (years) 35.7±7.12 37.1±6.40 36.4±6.78 37.3±7.41 
Height (cm) 160.6±8.00 174.6±6.66**** 168.1±8.78 167.5±10.1 
SBP (mmHg) 112.2±15.5 119.06±16.9** 115.6±16.5 118.2±17.0 
DBP (mmHg) 63.9±9.29 69.2±8.38**** 66.5±9.21 66.3±12.1 
HR (bpm) 75.7±12.7 76.1±12.1 75.9±12.3 73.1±11.1** 
HbA1c (%) 7.37±2.10 6.83±2.20 7.44±1.37 7.57±1.44 
eGDR (mg/kg/min) 8.53±1.88 7.65±1.76**** 7.69±2.31 7.06±2.34** 
Non-HDL (mg/dL) 112.8±33.0 115.4±32.5 114.1±32.7 119.5±39.2 
HDL (mg/dL) 64.9±16.1 53.2±15.1**** 59.2±16.6 58.3±16.2 
TG (mg/dL) 80.7±43.9 91.0±54.8 85.8±49.7 88.2±46.6 
WHR 0.82±0.09 0.92±0.07**** 0.87±0.09 0.90±0.09** 
BMI (kg/m2) 27.7±5.14 26.6±5.15 27.2±4.59 27.1±4.50 
Serum Creatinine 0.96±0.29 1.21±0.70 1.08±0.54 1.18±0.74 
eGFR (mL/min/1.73m2)  72.3±19.8 80.2±21.6** 76.1±20.1 74.4±26.1 
Albumin Excretion Rate 78.5±249.4 351.5±1115.9** 212.1±809.4 653.4±2593.4** 
WBC 6.40±2.1 6.50±2.0 6.44±2.01 6.46±1.93 
Ever Smoker (%) 37.1 42.9 40.0 31.7 
PW Medicationsd (%) 45.6 54.4 48.1 51.9 
Hypertension (%) 42.3 57.7 42.6 57.4 
E:I Ratio 1.15±0.12 1.13±0.13 1.14±0.12 1.13±0.12 
CAD (% with) 16.7 29.6* 23.1 30.9 
AIx (%) 24.7(1.38)c 21.3(1.36)c 23.0±11.0 NA 
AP (mmHg) 9.53(0.84)c 8.51(0.86)c 9.03±6.51 NA 
SEVR (%)  138.9(4.06)c 145.5(4.13)c 142.2±31.1 NA 
Abbreviations: Epidemiology of Diabetes Complications, EDC; systolic blood pressure, SBP; 
diastolic blood pressure, DBP; heart rate, HR; eGDR, estimated glucose disposal rate; high-
density lipoprotein, HDL, triglyceride, TG; waist-to-hip ratio, WHR; body mass index, BMI; 
kilocalories, KCAL; albumin excretion rate, AER; glomerular filtration rate, GFR; white blood 
cell count, WBC; low-density lipoprotein, LDL; blood pressure, BP; hypertension, HTN; 
augmentation index, AIx; augmentation pressure, AP; subendocardial viability ratio, SEVR. 
Data presented mean±SD or % 
a females and males compared within PWA population 
bThose included in PWA study compared to the rest of the Pittsburgh EDC study population.  
cheight adjusted mean(SE) 
dthose potentially affecting PWA measures: calcium channel blockers, ACE inhibitors, 
angiogensin receptor blockers, beta blockers, nitrates. 
* p<0.10; **p<0.05; ***p<0.01; ****p<0.001 
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 Table 20. Cross-sectional correlations between pulse wave analysis measures (AIx, AP and SEVR) and other 
factors measured at the 18-year follow-up examination in The Pittsburgh EDC Pulse Wave Analysis study 
population 
 AIx LnAP SEVR 
Systolic Blood Pressure (mmHg) .265*** .560**** -.437**** 
Diastolic Blood Pressure (mmHg) .396**** .292**** -.040 
HbA1c (%) .161* .160* .011 
Body Mass Index (kg/m2) .033 .089 -.161* 
Waist-to-Hip Ratio .159* .156* -.168** 
HDL-cholesterol (mg/dL) -.060 -.072 .157* 
eGDR -.160* -.267*** .203** 
White Blood Cell Count .266*** .289*** -.083 
Albumin Excretion Rate .111 ..272*** -.248*** 
E:I Ratio -.193** -.242*** .250*** 
Ever Smoker (%) .117 .138 -.284*** 
PWD Use (%) -.168** -.128 .031 
* p<0.10; **p<0.05; ***p<0.01; ****p<0.001 
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 APPENDIX A. REPEATABILITY STUDY 
Assessments of the repeatability of measures obtained by the SphymoCor pulse wave analysis 
device have previously been performed in various populations and are detailed in Appendix B.  
All of the studies listed found good to excellent intra- and/or inter-observer reproducibility for 
various measures obtained via applanation tonometry PWA measures.  
As part of the present research, a small repeatability study was completed. The 
parameters studied for repeatability were AIx, AP and SEVR however, data on other variables 
measured by PWA are included in the tables.  
Intra-observer  
 A small sample of participants from the Epidemiology of Diabetes Complications (EDC) 
study whom have Type 1 diabetes mellitus to determine the inter- and intra-observer 
reproducibility of variables obtained via applanation tonometry using the SphygmoCor  device 
(AtCor, Sydney, Australia). For the intra-observer part of the study, 1 observer recorded 2 
different measurements, 5 minutes apart on 17 different EDC participants. Table 21 shows 
descriptive data for SphgymoCor variables obtained during the intra-observer study.  The mean 
intra-observer difference was 0.42±9.51% for AIx, 0.42±2.53 mmHg for AP and 2.59±9.68% for 
SEVR. Figures 8 through 10 show the Bland-Altman plots for the individual data points. As 
illustrated in the graphs, all data points fell within 2 SD for AIx and SEVR, and all but 1 for AP. 
The coefficient of variation (CV) was for 20.3 for AIx, 26.0 for AP, and 7.8 for SEVR (Table 
21).  
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 Table 21. Intra-observer repeatability study on participants with type 1 diabetes (n=17) in The 
Pittsburgh Epidemiology of Diabetes Complications Study 
Variable Grand Mean S.D. Mean Difference 
S.D. of  
 Difference 
Coeff. Of 
Variation 
Aortic SBP 106.0 10.4 0.42 1.6 1.5 
Aortic DBP 67.1 9.0 -0.06 1.3 1.9 
HR 85.0 16.8 0.77 3.5 4.15 
AIX 23.5 10.6 0.42 4.8 20.3 
AIXHR75* 27.6 7.9 0.87 4.2 15.2 
AP 9.6 5.4 0.41 2.5 26.0 
APHR75* 11.6 5.7 0.87 2.2 19.0 
ED 286.5 27.2 0.94 7.4 2.6 
EDPER 40.1 5.6 0.42 1.3 3.2 
SEVR 124.7 35.0 -2.6 9.7 7.8 
ESP 94.4 9.5 0.53 2.2 2.33 
*Calculated only for those with a HR 55-110 bpm (n=15) 
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Figure 8. Bland-Altman plot for Augmentation Index (AIx) to show intra-observer reproducibility.  
Mean±SD difference (n=17): 0.42 ± 4.76% 
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Figure 9. Bland-Altman plot for Augmentation Pressure (AP) to show intra-observer reproducibility. 
Mean±SD difference (n=17): 0.42 ± 2.53 mmHg 
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Figure 10. Bland-Altman plot for Subendocardial Viability Ratio (SEVR) to show intra-observer reproducibility.  
Mean±SD difference (n=17): 2.59 ± 9.68%   
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 Interobserver 
 Table 22 contains the results of the inter-observer repeatability part of the study. Two 
different observers obtained SphygmoCor measurements on 7 different EDC participants within 
30-45 minutes of each other. Each observer measured radial blood pressure using a cuff prior to 
completing the applanation tonometry.  The mean±SD inter-observer differences were 
8.57±11.2% for AIx, 4.57±3.74 mmHg for AP, and 5.43±9.88% for SEVR.  Bland-Altman plots 
for inter-observer reproducibility (Figures 11-13) show that 2 of 7 data points lay outside 2 SD 
for AIx and AP, and 1 of 7 for SEVR. The coefficients of variation were 44.0, 42.9 and 6.74  for 
AIx, AP and SEVR, respectively, in the inter-observer analysis (Table 22). A limitation of the 
inter-observer study is that 3 measurements from one of the two observers were “Inconclusive” 
with an error indicating that the “Aortic T1 is out of range”.  Inconclusive measures indicate that 
some “noise” exists in the measurement and the measurement is not entirely clear.  To correct for 
this error, the measurement should be retaken as recommended by the company. However, the 
observer with inconclusive measurements was not the primary observer in this research study. 
The other observer for whom the intra-observer analysis was completed, was the primary PWA 
technician and completed over 90% of the measurements used in the present study. This observer 
showed excellent intra-observer reproducibility as previously discussed.  
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 Table 22.  Inter-observer repeatability variability in The Pittsburgh EDC Pulse Wave Analysis Repeatability 
Study 
Variable Grand Mean S.D. Mean Difference 
S.D. of 
Difference 
Coeff. Of 
Variation 
SBP 127.43 15.9 -6.57 8.14 6.39 
DBP 83.43 8.20 3.14 6.20 7.43 
Aortic SBP 116.71 12.6 -5.14 5.93 5.08 
Aortic DBP 84.29 8.32 2.57 6.27 7.44 
HR 80.57 17.2 0.29 3.40 4.22 
AIX 25.43 13.1 -8.57 11.2 44.0 
AIXHR75* 27.92 10.3 -10.2 10.7 38.3 
AP 8.71 5.77 -4.57 3.74 42.9 
APHR75* 9.62 4.54 -5.33 3.60 37.4 
ED 285.57 33.8 -3.14 7.82 2.74 
EDPER 37.64 4.34 -0.43 1.27 3.37 
SEVR 146.71 30.0 5.43 9.88 6.74 
ESP 108.07 10.0 -3.86 4.95 4.58 
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Figure 11. Bland-Altman plot for Augmentation Index (AIx) to show inter-observer reproducibility.  
Mean±SD difference (n=6): 8.57 ± 11.2% 
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Figure 12. Bland-Altman plot for Augmentation Pressure (AP) to show inter-observer 
reproducibility.  Mean±SD difference (n=6): 4.57 ± 3.74 mmHg 
 
 
Mean SEVR (%)
220200180160140120100
D
iff
er
en
ce
 in
 S
EV
R 
(%
)
20
10
0
‐10
‐20
+2 SD
‐2 SD
 
Figure 13. Bland-Altman plot for Subendocardial Viability Ratio (SEVR) to show inter-observer 
reproducibility.  Mean±SD difference (n=6): 5.43 ± 9.88% 
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 Biologic Variability Over Time 
In order to study variability over time, two different individuals were selected to have 
repeated measures on different days at varying times.  Since the SEVR variable has a defined 
cut-off value (150%), potential participants were screened and one with normal SEVR (>150%) 
and one with low SEVR (<150%) were selected. The person with the normal SEVR was a 26 
year old, healthy female without diabetes, no history of cardiovascular or renal disease who was 
not taking medications at the time and had a BMI of 18.5 kg/m2. The “abnormal” participant was 
a 50 year old woman, with a 26.4 kg/m2 BMI, without diabetes but with a history of 
hypertension, reporting use of an anti-hypertensive agent. The pulse wave analysis measures for 
each participant are presented in Table 23. As expected, mean values for AIx and AP were 
higher in the individual with abnormal screening values measurements compared to the one with 
normal values, while SEVR was lower. As illustrated in Figures 14 and 15, AIx and AP seemed 
to vary more over the 6 different time points in the individual with abnormal values. The highest 
AIx and AP values in this individual were at a BP of 130/68 mmHg and HR of 70 bpm 
(Measurement 2, Table 23b). By comparing measurement 2 to measurement 1 in this same 
individual, during which the HR was the same (70 bpm), DBP was very similar (68 mmHg) but 
SBP was much lower (110 mmHg), it can be seen that it was the increase in SBP that 
corresponded to the increased AP and AIx as well as a decreased SEVR (Figure 16).  SEVR 
seemed to vary more in the participant with normal screening values as shown in Figure 16. 
Interestingly, the lowest value in this individual was 145% at measurement 4, less than the 150% 
cut-off for normal. This SEVR measurement occurred when SBP/DBP were also at their lowest 
(92/52 mmHg) for this individual. It is worth mentioning that this measurement was taking 
within less than 10 minutes of this person eating a meal.  However, AIx and AP at this 
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measurement were similar to that in most other measures. AIx and AP in this individual were 
lowest when this person’s blood pressure and heart rate were at their highest, 106/84 mmHg and 
70 bpm, respectively. However, the BP was well below the cut-off for hypertension and the 
measurement corresponded with this individual’s lowest pulse pressure (PP=22 mmHg).  The 
highest PP in the abnormal individual (68 mmHg) corresponded with that persons highest AP (13 
mmHg) and AIx (27%) measures and her lowest SEVR (107%) and her lowest PP (40 mmHg, 
which is actually equal to the highest in the normal individual) corresponded to her lowest AP 
and AIx and highest SEVR.  
To summarize, there seems to be variability of PWA measures within an individual at 
different time points and variability may depend on the degree of arterial stiffness in an 
individual. Additional studies, with more than two individuals, should be performed to 
understand what factors affect these measures within an individual. 
 Table 23. Pulse Wave Analysis measures over time in one normal and one abnormal (based on SEVR) participant. 
21a. Normal subject (SEVR >150% at screening) 
 
SBP DBP aSBP aDBP HR AIX AP 
AIX 
HR75 
AP 
HR75 ED ED% SEVR ESP 
Measure 1 106 84 98 84 70 8 1 6 1 313 37 161 95 
Measure 2 104 64 92 65 64 17 4 11 3 303 32 183 86 
Measure 3 98 58 86 59 67 13 3 9 2 302 34 169 80 
Measure 4 92 52 80 53 70 17 5 14 4 313 37 145 74 
Measure 5 104 64 94 65 60 18 5 11 3 336 33 175 88 
Measure 6 106 68 94 69 62 14 3 8 2 305 31 193 89 
Mean 101.7 65.0 90.7 65.8 65.5 14.5 3.50 9.83 2.50 312.0 34.0 171.0 85.3 
SD 5.57 10.86 6.53 10.52 4.18 3.73 1.52 2.79 1.05 12.71 2.53 16.88 7.37 
21b. Abnormal Subject (SEVR<150% at screening) 
Measure 1 110 70 97 70 84 14 4 19 5 267 38 141 89 
Measure 2 130 68 116 70 88 27 13 33 17 291 43 107 104 
Measure 3 128 70 114 71 79 23 10 25 11 299 39 123 102 
Measure 4 112 64 97 65 93 16 5 25 9 272 42 114 86 
Measure 5 130 76 118 77 85 24 10 29 13 296 42 115 108 
Measure 6 128 74 113 76 98 18 7 30 13 266 44 108 102 
Mean 123.0 70.3 109.2 71.5 87.8 20.3 8.17 26.8 11.3 281.8 41.3 118.0 98.5 
SD 9.36 4.27 9.58 4.42 6.79 5.09 3.43 4.92 4.08 15.14 2.34 12.65 8.85 
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Figure 14. Augmentation Index (AIx) at 6 different time points, over a 2 week period in non-diabetic 
participants, one with abnormal PWA values at screening and one with normal values 
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Figure 15. Augmentation Pressure (AP) at 6 different time points, over a 2 week period in non-
diabetic participants, one with abnormal PWA values at screening and one with normal values. 
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Figure 16. Subendocardial Viability Ratio (SEVR) at 6 different time points, over a 2 week period in 
non-diabetic participants, one with abnormal PWA values at screening and one with normal values.  
 
 
 APPENDIX B. REPEATABILITY STUDIES FOR THE SPHYGMOCOR DEVICE 
Table 24. Repeatability studies for the SphygmoCor Pulse Wave Analysis device 
Author Primary Aim Study Population Sample Size 
Indices 
evaluated Results 
Frimodt-Moller, M et al  
Nephrol Dial Transplant 
2007 Nov 7 epub 
Evaluate intra- and 
inter-observer and 
day-to-day 
reproducibility of 
PWA and PWV  
Pre-dialysis patients with 
CKD stages 3-5 
Mean GFR = 
25.3ml/min/1.73m(2) 
19       AIx 
SEVR 
aPP 
Mean inter-observer 
differences: 
AIx: 0.9±15.8% 
SEVR: -0.9±15.2% 
aPP:1.4±13.3mmHg 
Mean day-to-day 
differences: 
AIx: 2.6±11.2%,  
SEVR: -0.4±24.7% 
aPP:0.3±20.9 mmHg 
Mean Intra-observer 
differences: 
AIx: 1.9±10.6%,  
SEVR: -1.1±17.4% 
aPP:0.3±4.0 mmHg 
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 Table 24 Continued 
Author Primary Aim Study Population 
Sample 
Size 
Indices 
evaluated Results 
Crilly M et al 
Vasc Med 
2007;12(3):189-197 
Assess within- and 
between-observer 
repeatability of 
ED%, AIx@75 and 
SEVR% 
Ambulant patients in 
sinus rhythm 
20  
(16 male) 
AIx@75 
ED% 
SEVR% 
Inter-observer difference (mean of 2 
readings):  
ED% - 0.3±2.0 
AIx@75 1.0±3.9 
SEVR%: 1.7±14.2 
Inter-observer based on 1 
measurement:  
ED% - 0.3±3.3 
AIx@75 1.7±6.9  
SEVR%: 0.6±22.6 
Intra-observer difference: 
Observer 1 
ED% 0.0±5.4 
AIx@75 1.5±7.0 
SEVR%: 1.7±39.0 
Observer 2 
ED%  0.1±3.8 
AIx@75 0.1±8.0 
SEVR%: 0.6±23.3 
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Table 24 Continued 
Author Primary Aim Study Population 
Sample 
Size 
Indices 
evaluated Results 
Papaioannou TG et al 
J Clin Monit Comput 
2004;18(2):137-44 
To assess 
reproducibility  of 
aortic AIx in patients 
with low blood pressure 
Patients with 
cardiogenic shock 
due to acute MI who 
underwent 
mechanical assistance 
with intraaortic 
balloon pump 
19 AIx AIx range:30-184% 
Intra-observer difference: 
0.10±5.82% 
Savage MT et al 
Clin Sci (Lond). 
2002;103:59-65 
To assess the 
reproducibility of PWA 
in patients with chronic 
renal failure 
Patients with chronic 
renal failure (71 pre-
dialysis, 67 dialysis 
and 27 transplant), 
and 27 healthy 
controls 
188 aMBP 
AIx 
SEVR 
Inter-observer difference 
AIx:0±3% 
MBP: 1±4 mmHg 
SEVR: 1±29% 
Intra-observer difference 
AIx:0±4% 
MBP: 0±3 mmHg 
SEVR: 0±18% 
Wilkinson IB et al 
J Hypertens 
1998;16(12 Pt2):2079-84 
To determine the 
reproducibility of pulse 
wave velocity and AIx 
measured using PWA 
Subjects with and 
without a range of 
CV risk factors 
24 PWV 
33 AIx 
PWV 
AIx 
AIx:  Range = -15.0-+45.0% 
 Mean±SD = 19.6±12.0% 
Intra-observer difference:  
AIx: 0.49±5.37% 
Abbreviations: Pulse-wave analysis (PWA), Pulse-Wave Velocity (PWV), Augmentation Index (AIx), Mean Blood Pressure (MBP), 
Sub-endocardial Viability Ratio (SEVR), Ejection Duration % (ED%), Augmentation Index at Heart Rate of 75 bpm AIx@HR75, 
aortic Pulse Pressure 
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